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Abstract
The pharmaceutical industry is presently facing several obstacles in developing oral drug
delivery systems. This is primarily due to the nature of the discovered drug candidates.
The discovered drugs often have poor solubility and low permeability across the gastro
intestinal epithelium. Furthermore, they are often degraded before they can be absorbed.
The result is low bioavailability of the drugs. To overcome these challenges, better drug
delivery systems need to be developed. Recently, micro systems have emerged as promising
candidates to solve the challenges of poor solubility, low permeability and degradation.
These systems are for the majority based on traditional materials used in micro technology,
such as SU-8, silicon, poly(methyl methacrylate). The next step in developing these new
drug delivery systems is to replace classical micro fabrication materials with biodegradable
polymers. In order to successfully do this, methods for fabricating micro structures in
biodegradable polymers need to be developed.
The goal of this project has been to develop methods for micro fabrication in biodegradable
polymers and to use these methods to produce micro systems for oral drug delivery. This
has successfully been achieved by fabrication of micro container systems made of poly(L-
lactic acid) and polycaprolactone.
To achieve this, polymer solutions have been developed using the theory of Hansen’s
solubility parameters. The solutions are used to fabricate polymer ﬁlms by spin coating,
which are used in the fabrication of micro devices for oral drug delivery. Films consisting
of both polymer and pharmaceuticals have also been developed by spin coating. A deep
reactive ion etch producing sloped sidewalls for stamp production has been developed.
The sloped sidewalls ensure a successful separation of stamp and ﬁlm after patterning.
Large scale methods for ﬁlling of micro reservoirs based on embossing, screen printing and
solvent casting have been developed.
In vitro drug release experiments on both type of micro devices have been performed.
The experiments show that most of the drug is released from the developed devices.
Additionally, it has been shown that it is possible to control the release of drug by adding
polymeric coatings.
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vDansk resume´
Den farmaceutiske industri st˚ar i øjeblikket over for ﬂere forhindringer, n˚ar de udvikler
medicin administreret oralt, primært p˚a grund af typen af lægemiddelkandidaterne. Lægemi-
dlerne er ofte svært opløselige og har en lav permeabilitet i gastrointestinalt epithel. Desu-
den nedbrydes de ofte, før de bliver absorberet. Resultatet er en lav biotilgængelighed af
lægemidlerne. For at overvinde disse udfordringer, er det nødvendigt at udvikle mediciner-
ingssystemer.
For nylig er mikrosystemer kommet frem som kandidater til at løse problemerne. Størstedelen
af disse systemer er baseret p˚a materialer, der ofte anvendes i mikroteknologi, s˚asom SU-
8, silicium, poly(methyl methacrylate). Det næste skridt i udviklingen af nye mediciner-
ingssystemer er at erstatte klassiske mikrofabrikationsmaterialer med bionedbrydelige poly-
merer. For at kunne gøre dette, skal der udvikles metoder til at fremstille mikrostrukturer
i bionedbrydelige polymerer.
Ma˚let med dette projekt har været at udvikle metoder til mikrofabrikation af bionedbry-
delige polymerer og at anvende disse metoder til at fremstille systemer, der kan bruges
til oral medicinering. Dette er opn˚aet ved fremstilling af mikrocontainere lavet af poly
(L-lactid acid) og polycaprolactone. Endvidere er et mikrosystem baseret p˚a stablede lag
af polymer og lag af polymer blandet med medicin fremstillet.
For at fremstille mikrosystemerne, er polymeropløsninger blevet udviklet ud fra Hansens
teori om opløselighedsparametre. Opløsningerne bruges til fremstilling af polymerﬁlm ved
spin-coating. Disse ﬁlm benyttes ved fremstilling af mikrosystemer til oral medicinering.
En ﬁlm, som best˚ar af b˚ade af polymer og lægemiddel, er desuden ogs˚a blevet udviklet
ved spin-coating.
Dybe reaktive ion ætse, der producerer skr˚a sidevægge til stempel produktionen, er blevet
udviklet. De skr˚anende sidevægge sikre en vellykket adskillelse af stempel og ﬁlm efter
stempling. Metoder til fyldning af mikroreservoirer er blevet udviklet. Disse er baseret p˚a
prægning, silketryk og solvent støbning.
Der er udført in vitro lægemiddelfrigivelsesforsøg p˚a begge mikrosystemer. Disse viser, at
næsten al lægemidlet frigives fra systemerne. Endvidere har det vist sig, at det er muligt
at kontrollere frigivelsen af lægemidlet ved tilsætning af polymerbelægninger.
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Chapter 1
Introduction
Oral delivery is often the preferred route of drug administration since it provides good
compliance for the patients and no need for health professionals. However, the phar-
maceutical industry is presently facing several obstacles when developing oral delivery
systems, primarily due to the nature of the discovered drug candidates. Generally drug
candidates can be divided into two categories; small molecules and biological compounds.
The discovered active small molecules often have a poor solubility and a low permeabil-
ity across the gastro intestinal (GI) epithelium. Biological compounds, like proteins and
nucleic acids, are degraded in the GI tract and have a poor permeability. Both types
of compounds therefore require development of special drug delivery systems to reach a
satisfactory oral bioavailability.
Traditionally, oral drug delivery is based on compressed tablets and capsules. Recently,
micro and nano particles as well as micro systems have emerged as possible drug carriers
that can solve the challenges described above [1, 2]. The aim of the project is to develop
and improve such micro systems for drug delivery. The PhD study is carried out as part
of a larger consortium, NAnoMEChanical sensors and actuators, fundamentals and new
directions (NAMEC) - a VKR Centre of Excellence, working on micro systems for oral
drug delivery among other technologies such as sensors. The main collaborators for the
oral drug delivery project consist of engineers from the Department of Micro and Nan-
otechnology (DTU Nanotech), at the Technical University of Denmark and pharmacists
from the Department of Pharmaceutics and Analytical Chemistry at the University of
Copenhagen (KU Farma). The following sections will explain the vision of the NAMEC
drug delivery project as well as introduce the collaborating parties and the main tasks set
forth for each party.
1.1 NAMEC project & vision
The main goal of the drug delivery project in NAMEC is to realize and characterize micro
systems for oral administration of drug. It is the vision of this project to develop a general
drug delivery system that can deal with the challenges described above no matter which
kind of drug the system carries. The system should have a protective shell around the
1
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drug to protect the drug from degradation in the stomach. Technologies controlling the
release should be developed to control the release kinetics such as time and position. The
system should adhere to the intestinal epithelial surface and release the drug unidirectional
across the epithelial cell surface to increases the drug uptake. Ideally, this should prevent
drug from passing through the gastrointestinal tract without being absorbed. Formula-
tions aiding the dissolution and enhancing the permeability across the gastro intestinal
epithelium should be developed. Additionally, the devices should be easy to swallow to
increase patient compliance.
1.2 Device
A device capable of performing the tasks described above is sketched in ﬁgure 1.1. The
aim is to keep the device as simple as possible. This means that no electronics will be
involved in the system. Furthermore, the system should consist of materials approved for
oral drug delivery. As a guideline, materials approved by the food and drug administration
(FDA)1 should be used in order to minimize authorization procedures. The device consists
of a container with the purpose of protecting the drug in the GI tract. Preferably, the
container should be made in biodegradable polymers which are approved by the FDA. For
this purpose poly(L-lactic acid)(PLLA) and polycaprolactone (PCL) are chosen. Besides
the container, the device consists of a membrane or coating that should enable drug to be
released at a speciﬁc time and/or place in the GI tract. Additionally, the device should
enhance the solubility and the permeability of the active pharmaceutical ingredient (API)
and thereby enhance bioavailability. This is to be obtained by improved drug formulations
and by having a mucoadhesive device, which attaches to the intestine wall and performs
a unidirectional release of the API across the intestine wall. The mucoadhesion can be
obtained by polymeric coatings[3] or by chemical surface modiﬁcations[4]. As for the drug
formulation, several options exist that can enhance the solubility and permeability, such
as lipid based formulations [5], supersaturating drug delivery systems [6], solid dispersions
Figure 1.1: Diagram showing the diﬀerent parts of the drug delivery system.
1The FDA is the American government agency, whom authorizes compounds for use in foods and
drugs.
1.3. GOAL OF THE PHD 3
[7], amorphous drug formulations[8] and nano crystalline formulations [9]. In determining
the size of the device the following consideration are made. The size of the device should
allow for easy swallowing as this can be a problem for patients. Generally, people can
detect particles with a size of a few hundred microns in the mouth [10]. Thus it can be an
advantage to keep the size of the device below a few hundred microns. In terms of drug
delivery, the bigger the device is, the fewer devices are needed for a dose. An estimate
of micro devices needed for an erythropoietin dose of 0.03mg is found to be 230.000 [11],
assuming a device measuring 40 μm in diameter and 6.2 μm in height. Thus, having
larger devices could reduce this number signiﬁcantly. Little is known about mucoadhesion
of micro devices and the eﬀect of size on this property. It is likely that the device would be
dragged along by intestinal ﬂuids if it sticks too far out of the mucus layer. Additionally,
there is the issue of handling the devices, which become signiﬁcantly easier the larger the
devices are. With these factors in mind, it is decided to fabricate micro container proto-
types with a characteristic length of 300 μm.
The development of the drug delivery device is divided into work packages consisting of; (1)
micro container fabrication, which is my work package, (2) lid and coatings, (3) mucoad-
hesion, (4) ﬁlling of micro containers, drug matrix and (5) drug formulation. The DTU
Nanotech personnel is responsible for the container fabrication, the container ﬁlling as well
as the lid and coatings while the KU Farma personnel is responsible for mucoadhesion,
drug matrix as well as drug formulations.
1.3 Goal of the PhD
This section lists the goals set forth at the beginning of the PhD. The goals are based on
the vision and the device described above and the ﬁrst work package.
• Develop fabrication methods for micro structuring of biodegradable polymers.
• Fabrication of micro containers in biodegradable polymers.
• Develop methods that can be up scaled for large scale production.
1.4 Model drug
Pharmaceutical active ingredients are often divided into four categories classifying them
by solubility and permeability [12]. For the class 1 drugs, both the permeability and
solubility is high, while both are low for the class 4 drugs. Class 2 has a high permeability
and low solubility and vice versa for class 3 drugs. As a model drug, a class four drug is
chosen as it represents the challenges facing most newly developed drugs [13]. The choice
of drug is furosemide. The drug is used for treating edema and hypertension cite [14, 15].
1.5 Review of existing research
This section presents the most relevant research concerning micro devices for oral drug
delivery. In terms of size, micro devices for oral drug delivery position themselves between
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conventional tables and research ﬁelds such as micro- and nano-particles, vesicles, micelles
etc. These research ﬁelds represent alternative technologies to the micro devices and will
not be covered here. The research ﬁeld concerning micro devices similar to the one de-
scribed in section 1.1 emerged a little more than a decade ago. The ﬁrst micro system
matching the vision described in section 1.1 is found in a patent dating 01/06/2000 and
published 03/12/2002. The patent idea is published in an article by Martin and Grove
[1]. Both have since demonstrated the idea by realizing silicon micro particles [16, 17].
Since then, several research groups around the world have worked within the ﬁeld of micro
devices for oral drug delivery. A number of reviews [18, 19, 20, 21, 22] outline most of
the work carried out and the future potential. To give an overview of the current state of
the art, the work of four research groups are highlighted in the following paragraphs and
summarized in table 1.1 and ﬁgure 1.2.
The group of Tejal Desai at University of California, San Francisco has carried out a lot
of research on mucoadhesive micro devices for oral drug delivery and their work repre-
sents the state of the art within the ﬁeld. Several micro systems have been realized and
optimized during the past decade. Their ﬁrst devices where micro wells fabricated in
silicon using standard silicon technology [26]. The structures had a height of 2 μm with
a 1 μm deep reservoir and a width of 50 to 150 μm. Improved bioadhesion was shown
by chemically modifying the device surface and attaching lectin. In vitro experiments
on CaCo-2 cells showed improved bioadhesion. Desai et al. have later improved these
devices several times. Micro devices with multiple drug reservoirs have been fabricated
[4]. Devices have been realized in poly(methyl methacrylate) (PMMA)[27], poly(lactic-co-
glycolic acid) (PLGA), gelatine and SU-8.[28]. Devices have typical feature size of 50-200
μm in width and height of 5-10 μm. Testing of drug release and bioadhesion of these
devices is done in vitro [29, 30]. The latest work describes bioadhesive micro devices with
multiple reservoirs made in PMMA [23]. The device has three compartments containing
three diﬀerent types of drug and measures 200 μm in width and 7.5 μm in height. The
compartments measure 60 μm and are 5 μm deep. In vitro drug release was tested in a
CaCo-2 cell setup. Figure 1.2(a) shows an image of the latest device published.
The group of Joseph DiSimone at University of North Carolina has developed a fabri-
cation method, Particle Replication In Non-wetting Templates (PRINT), which is used to
produce micro and nano particles for drug delivery. The method enables the fabrication
of individual particles. The non-wetting technology avoids the creation of a residual layer
that usually connects particles made by embossing. Figure 1.2(b) shows a schematic of
the PRINT technology. Particles have been fabricated with sizes ranging from 200 nm
to 7 μm [31, 32, 24, 33]. The particles have been fabricated in many diﬀerent materials
such as poly(ethylene glycol) (PEG), Poly(L-lactic acid) (PLLA) and PLGA and tested
in vitro and in vivo.
The group of Kanji Takada at Kyoto Pharmaceutical University has made devices for
oral drug delivery consisting of solvent cast layers of ethyl cellulose, cellulose and a pH
sensitive coating, such as Eudragit R© or HP-55 R©. The layers are stacked upon each other
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and merged to one piece by heating. The devices are cut out in squares of 3 by 3 mm and
are 115 μm high. [34, 35, 25]. The latest work follows the same principles and includes
membranes made of polycaprolactone (PCL) and poly lactide acid (PLA) polymers [36].
The devices are round with a diameter of 1.85 mm and a height of 0.15 mm. In vitro and
in vivo characterization is presented. The micro device is shown in ﬁgure 1.2(c).
The group of James L. Lee at Ohio State University has done considerable research within
the ﬁeld of micro devices for drug delivery [11, 37, 38]. They have fabricated micro wells
ranging in size from 2-10 μm in height and 30-80 μm in width. Figure 1.2(d) shows the
(a) Desai et al. [23] (b) DiSimone et al. [24]
(c) Takada et al. [25] (d) Lee et al. [11]
Figure 1.2: The ﬁgure shows the state of the art devices fabricated by selected groups and
a schematic of the PRINT technology.
6 CHAPTER 1. INTRODUCTION
Table 1.1: Comparison of micro systems developed for oral drug delivery similar to what
is described in US patent number: 6355270 B1.
Group Material Size
Height/width
Demonstration
level
Process type
Desai et al Silicon
SU-8
PMMA
PLGA
1-10μm/
50-200μm
In vitro Lithography
molding
Takada et al. cellulose
Eudragit R©
HP-55 R©
PCL
PLA
115-185μm/
1.85-3mm
In vitro
In vivo
Solvent casting
Lee et al.
Micro wells: PEGMA
PEGDMA
PLGA
Chitosan
2-10μm/
30-80μm
In vitro Molding
soft lithogr-
pahy
lithography
mm Containers PCL 1.5mm/
4.5mm
In vivo Molding
DeSimone et al. PLLA
PLGA
PEG
200nm-7μm/
200nm-7μm
In vitro
In vivo
PRINT R©
fabricated micro wells. The micro devices are realized in PEGMA, PEGDMA, PLGA
and Chitosan. The micro devices range from simple wells to self folding micro containers.
Other research performed by the same group includes containers with sizes of 1.8 mm
height and 4.5 mm width made in PCL [2, 39] and similar devices made in gels [40]. The
demonstration level of drug delivery includes the use of animal intestines in experiments
as well as animal tests.
1.6 Novelty
The novelty of this work consists of the following; fabrication of micro systems in biodegrad-
able polymers that are approved by FDA. Development of large scale fabrication of micro
systems for drug delivery by hot embossing of biodegradable polymers. The development
of methods for large scale ﬁlling of micro containers.
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1.7 Thesis outline
This section presents an overview of the chapters in the thesis and a short summary of the
content of the individual chapters. The thesis is divided into ten chapters plus appendices.
The ﬁrst appendix is a list of scientiﬁc contributions made during the PhD study. Following
this is published work, then a list of polymers considered for the project and data sheets
for PCL and PLLA. Lastly process recipes and process data are included. Each chapter
starts with a short introduction and ends with a summary of the most important ﬁndings.
Chapter 2 - Polymers The chapter describes the theory of solubility used for making
solutions. It highlights characteristics of the most used polymers. Finally, it de-
scribes the spin coating method used for ﬁlm deposition along with spin curves for
PCL and PLLA.
Chapter 3 - Drug matrix This chapter describes the development of a drug matrix
consisting of PCL and furosemide. The chapter shows how Hansen’s solubility pa-
rameters can be used for complex systems with multiple compounds. Furthermore,
the drug matrix is characterized by microscopy and X-ray diﬀraction.
Chapter 4 - Stamps This chapter explains the fabrication of the diﬀerent stamps made
in the project. The stamps are later used for embossing of polymers. Stamps in
three diﬀerent materials are made; SU-8, silicon and nickel. Finally, a deep reactive
ion etch process is developed to tune the slope of the side walls.
Chapter 5 - Micro containers The fabrication of the diﬀerent micro containers is de-
scribed in this chapter along with an introduction to hot embossing. Micro containers
are made in SU-8, PLLA and PCL.
Chapter 6 - Filling The ﬁlling of the diﬀerent micro containers is shown in this chapter.
Three diﬀerent methods for ﬁlling are tested and compared.
Chapter 7 - Drug delivery In vitro drug release from the drug matrix along with the
drug release from micro containers are described in this chapter. The drug release
is tested mainly by μ-dissolution. A control experiment using a UV-imager is made.
Chapter 8 - Conclusion The conclusion summarizes the most important results ob-
tained in the thesis.
Chapter 9 - Outlook The outlook highlights possible directions for future development
of micro devices for drug delivery.
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Chapter 2
Polymers
This chapter covers the theory of solubility, the characteristics of the most used polymers
in this project, preparation of biopolymer solutions and ﬁlm fabrication by spin coating.
In this project alot of emphasis is on the fabrication of biodegradable micro containers
made in poly-L-lactide acid (PLLA) and polycaprolactone (PCL) which are approved by
the FDA. These polymers will be covered in depth in this chapter while less frequently
used polymers and materials will be covered to some degree.
2.1 Solubility theory
This section contains the solubility theory used throughout the project in the development
of solutions for various purposes. First, an introduction to Hansen’s solubility parameters
(HSP) is given and the thermodynamic theory behind HSP is presented. The parameter
space and solubility concept of HSP is explained. Once the concepts of HSP are established
an example of its use in choosing solvent(s) for a given polymer is presented. Furthermore,
considerations of solubility of systems with multiple components are given.
2.1.1 Introduction
The theory of solubility is a complex matter and several diﬀerent approaches exist. Flory-
Huggins are among the ﬁrst to derive a solubility theory. The Flory-Huggins solubility
theory is based on change in Gibbs free energy. The solubility is deﬁned by the interaction
parameter χ [41] . The approach to solubility that will be addressed in this chapter is
the one of Hildebrand and Hansen. The theory is based on the cohesive energy. The
Hildebrand parameter δ is an interaction parameter like Flory-Huggins. The theory is ap-
plicable to associated solutions and is based on the principle of ”like dissolve like”. Thus,
materials with similar δ parameters are likely to be miscible.
Hansen solubility parameters (HSP) expand the Hildebrand solubility parameter δ into
three parameters, creating a three dimensional parameter space. The use of three param-
eters oﬀers a more accurate treatment of solubility than that of Hildebrand. Although
HSP improves the theory of Hildebrand, limitations apply to the theory as molecular
shape and size are not taken into account. HSP is an empirical approach to solubility
9
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and thus material parameters have to be determined in order to use HSP. Luckily many
people have worked with HSP and thus HSP parameters can be found for more than 2000
compounds[42]. If a speciﬁc compound of interest is not cataloged with HSP data, the
reader is reﬀered to [43] for details on how to obtain HSP data.
For further information on the diﬀerent solubility theories, see [43, 41, 44].
2.1.2 Parameter space & solubility
Hansens solubility parameters use cohesive energy to predict solubility. The cohesive
energy can be divided into three components, the non polar atomic interactions ED, the
permanent dipole- permanent dipole molecule interactions EP and the hydrogen bonding
interaction EH . The total cohesive energy is given by:
Ecohesive = ED + EP + EH (2.1)
Dividing with the molar volume, one arrives at the Hildebrand and Hansen parameters δ
[MPa
1
2 ]:
Ecohesive
Vmol
= δ2 = δ2D + δ
2
P + δ
2
H (2.2)
The three parameters determine the coordinate of a compound in Hansen space. The
parameters can either be found experimentally, see [43] or they can be calculated using
various models included in HSPiP[42]. The coordinate is the center of the Hansen solubility
sphere. The radius of the sphere is determined via experiments. The material in question
is immersed in a series of test solvents with diﬀerent HSP coordinates. By determining
whether or not the material dissolves, the solvent is given a score of either 1 if it dissolves
(good) or 0 if it does not dissolve (bad). The distance between the sphere center coordinate
and the test solvents is then calculated using the following formula:
R2a = 4(δD1 − δD2)2 + (δP1 − δP2)2 + (δH1 − δH2)2 (2.3)
An interaction radius R0 is deﬁned such that; solvents lying outside the interaction radius
are considered bad solvents (score 0) and solvents lying inside the interaction radius are
considered good solvents (score 1). By iteration of the test solvents, the interaction radius
R0 is determined. The uncertainty of R0 depends on the number of test solvents and
their HSP coordinates. For easy recognition of good and bad solvents, the RED number
is introduced as the ratio of distance between a solvent and the sphere center and the
interaction radius:
RED = Ra/R0 (2.4)
If the RED number is below 1 the aﬃnity of the solvent is good and if the RED number
is above 1, the aﬃnity of the solvent is bad. Thus, a solvent with a coordinate outside the
sphere will not dissolve the compound while a solvent inside will dissolve it. Figure 2.1
shows a two dimensional representation of the sphere concept. In practise the uncertainty
inherent from the calculation of HSP data give rise to a grey area for solvents with a RED
number close to 1. Solvents just outside the sphere might dissolve the material and vice
versa.
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Figure 2.1: Two dimensional schematic of the Hansen sphere concept. Solvents with a
RED number above 1 are outside the sphere and categorized as bad solvents. Solvents
inside the sphere are considered good.
2.1.3 Example - choosing a solvent for polycaprolactone
The following is an example of how to use HSP to select a solvent for polycaprolactone
(PCL). Table 2.1 shows a set of selected solvents and their corresponding HSP data [45].
It is seen that Dioxolane and Methylene dichloride have a RED number below 1 and are
good candidates for dissolving PCL. Ethyl acetate is just at the border of the interaction
radius and might interact with PCL by either dissolving or swelling PCL.
From experiments it is known that methylene dichloride is a good solvent for PCL. Ethyl
acetate swells the PCL, but does not dissolve it and neither acetone nor 2-propanol dissolve
PCL. Depending on the application of the solution some solvents might be favored over
others. I.e. in the case of spincoating it can be an advantage to have a solvent which does
not evaporate fast at room temperature and thus baking of the resist is needed to solidify
it. Toxicity could be another important factor to consider when choosing a solvent. HSP
does not help to make those decisions, it only provides a selection of possible solvents.
2.1.4 Multiple component systems
When dealing with multiple component systems several cases arise. The following exam-
ple outlines some of the possibilities and limitations of HSP as a tool. For the ease of
drawing and explaining, the following example will be sketched in two dimensions, though
remember that HSP is a three dimensional parameter space. Figure 2.2 shows a situation
with two compounds (spheres 1 and 2) and three diﬀerent solvents (black dots). If one
wants to dissolve both compounds one needs a solvent that matches the overlapping area
(volume). In this example that ﬁts with solvent 1. In the situation that no solvent lies
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Table 2.1: The table shows the HSP data for a selected set of solvents for polycaprolactone.
The table is sorted by the RED number. It is seen that Dioxolane and Methylene dichloride
have a RED number below 1 and thus are good candidates for dissolving PCL.
Solvents δd δp δh RED
1,3-Dioxolane 18.1 6.6 9.3 0.48
Methylene Dichloride 17 7.3 7.1 0.78
Ethyl Acetate 15.8 5.3 7.2 1.02
Vinyl Acetate 16 7.2 5.9 1.22
Methyl Acetate 15.5 7.2 7.6 1.26
p-Xylene 17.8 1.0 3.1 1.71
Acetone 15.5 10.4 7.0 1.79
Toluene 18 1.4 2.0 1.9
2-Propanol 15.8 6.1 16.4 2.17
Figure 2.2: 2d schematic of a multiple compound HSP system. Sphere 1 and 2 represent
two diﬀerent compounds. The grey area shows the overlapping HSP areas of compound 1
and 2. Solvent 1, 2 and 3 represents diﬀerent solvents. The line between solvent 2 and 3
shows the possible HSP values when mixing the solvents.
in the overlapping (volume), choosing two solvents on opposite sides of the overlapping
spheres will dissolve the material if mixed in the right way. The combined HSP values
of a solvent system are linearly additive and thus it is possible to achieve HSP values
on a straight line connecting two solvents in HSP space. To dissolve a two component
system one has to match the solvent(s) HSP values to the overlapping sphere volumes of
the given compounds. The line between solvent 2 and solvent 3 shows the possible HSP
values when a combination of the solvents are mixed. In this example, a mix around half
and half of each solvent, will give a value inside the overlapping region of sphere 1 and
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sphere 2, thus dissolving both compounds. The trick of mixing solvents to match a speciﬁc
HSP value is valid for a single compound as well. When mixing solvents it is important to
take the boiling point into account. For example solvent 1 evaporates fast while solvent 2
evaporates slowly. The solvent mixture will alter its composition over time if it is allowed
to evaporate. Thus the HSP values of the system will change when the ratio of solvent
change. If the system is delicate and responds fast to the change in solvent ratio, one of the
components might go out of solution while the other will remain in solution. Depending
on the application of the blend this can either be a feature or an issue.
2.1.5 HSP remarks
The strength of HSP lies in the large amount of data available to the user. Data can be
found in Hansen’s solubility parameters, a users handbook[43] or on the web[42]. It can
be of great help to use the HSPiP program, which has all data available in data sheets and
tools to help you with calculations and comparisons. It should be noted that HSP values
are aﬀected by temperature, which the theory does not include. Thus, data obtained
at room temperature might be signiﬁcantly diﬀerent if used at extreme temperatures.
Molecular size and shape are not considered and can play a role in solubility. Regardless
of its limits, HSP can be of great help when choosing solvents, as it provides the user with
a selection of possible solvents to use.
2.2 Biopolymers
This section contains relevant physical and chemical properties for the two polymers,
PCL and PLLA. Both polymers belong to the polyester family and their structures are
shown in ﬁgure 2.3. Both polymers are categorized as biopolymers [46] and they are both
biodegradable, though only PLLA is a biobased polymer while PCL is a fossil fuel based
polymer. PLLA can be produced from diﬀerent organic materials such as corn starch and
sugercane. PCL is made from -caprolactone which is cyclic ester. The two biopolymers
(a) (b)
Figure 2.3: Structural formula of a) polycaprolactone and b) polylactic acid.
are selected for their good properties for fabrication and both polymers are successfully
used in the fabrication of ﬁlms [47, 48, 49] and various drug delivery systems as well as
for scaﬀolds for tissue engineering [50] [51]. Although both polymers are used for similar
purposes their properties are quite diﬀerent. Table 2.2 lists the physical properties for
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Table 2.2: List of properties for chosen biopolymers based on peer reviewed literature.
Density (ρ , in g/cm3), tensile properties: tensile strength (σ, in MPa), tensile modulus
(E, in GPa) and ultimate strain (, in %), glass transition temperature (Tg, in
◦C) and
melting point (Tm, in
◦C) [52]
Properties Limits Polymers
PLA PLLA PCL
ρ (g/cm3) Upper 1.21 1.24 1.11
Lower 1.25 1.30 1.146
σ (MPa) Upper 21 15.5 20.7
Lower 60 150 42
E (GPa) Upper 0.35 2.7 0.21
Lower 3.5 4.14 .44
 (%) Upper 2.5 3 300
Lower 6 10 1000
Tg (
◦C) Upper 45 55 -60
Lower 60 65 -65
Tm (
◦C) Upper 150 170 58
Lower 162 200 65
PCL, PLA and the speciﬁc L conﬁguration of PLA referred to as PLLA. The table shows
the polymer density (ρ , in g/cm3), tensile strength (σ, in MPa), tensile modulus (E, in
GPa) and ultimate strain (, in %), glass transition temperature (Tg, in ◦C) and melt
point (Tm, in ◦C). The suppliers datasheets for PLLA and PCL used in the project can
be found in appendix D & E. When comparing PCL to PLLA it is clear that they are very
diﬀerent polymers. For fabrication purposes such as hot embossing the Tg is an important
parameter. While PCL has a very low Tg around -60
◦C, PLLA has a Tg of around 60
◦C. Coupled with the diﬀerences in young’s modulus and ultimate strain, PLLA stands
out as a ﬁrm polymer while PCL is a rubbery polymer at room temperature. The use of
these two diﬀerent polymers provides a versatile basis for future development of diverse
micro systems and fabrication techniques.
2.3 Solutions
In order to work with the polymers and fabricate ﬁlms, the polymer granulates need to be
dissolved in a solvent. Figure 2.4 shows the granulates before dissolution, while dissolving
and the ﬁnal solution. The dissolution of the polymer can take from minutes to a couple
of days depending on the polymer and the concentration of polymer in the solution. Table
2.3 shows a list of solvents and whether they dissolve our model drug furosemide and the
polymers poly(acrylic acid) (PAA), PCL and PLLA. The amount of material dissolved is
0.5 g for the drug and 1 g for the polymers in 10 ml of solvent. The amount of material a
solvent can dissolve is of importance when preparing solutions for spin coating. The more
viscous a solution is the thicker a ﬁlm can be produced. Dichloromethane (DCM) is a good
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(a) (b) (c)
Figure 2.4: The ﬁgure shows the polymer as recieved a), while dissolving b) and in solution
c). In this case it is PLLA in DCM 25wt%.
Table 2.3: Solubility of polymers and furosemide medicine. 10 ml of solvent used.
solvents Furosemide 0.5 g PAA 1 g PCL 1 g PLLA 1 g
Acetone Soluble Slightly Soluble Not Soluble Not Soluble
Dichloromethane Not Soluble N A Soluble Soluble
Ethanol Not Soluble Soluble Not Soluble Not Soluble
Isopropanol Not Soluble Soluble N A N A
DMSO Soluble Soluble N A N A
Water Not Soluble Soluble Not Soluble Not Soluble
solvent for both PCL and PLLA. Solutions containing up to 30 wt% of polymer (to solvent)
are prepared for both polymers. For highly concentrated solutions, the dissolution process
is accelerated by heating the solution to 50 ◦C during the dissolution. The solution is
cooled to room temperature when the dissolution process is complete. Further information
on solutions and in particular multi component solutions is given in chapter 3, while the
applied theory is covered in section 2.1.
2.4 Polymer ﬁlms
The following section describes how the polymer ﬁlms used in the project are fabricated
and how diﬀerent fabrication techniques are used to tune the adhesion of the polymer
ﬁlms to the substrates. The majority of the polymer ﬁlm fabrication is done by spin
coating. Other methods such as solvent casting and sheet extrusion have been used to a
small extend to fabricate polymer ﬁlm. The PLLA sheets are fabricated by collaborators
at DTU RISØ, while the solvent casting is performed in our own lab. Both techniques are
used to a little extend as spin coated ﬁlms have performed better for our processes. Spray
coating is used in the project for ﬁlm deposition. That work is carried out by colleagues
in the group. For this reason spin coating is the only method described in this section.
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2.4.1 Spin coating
Spin coating is a fabrication technique that is widely used for deposition of thin ﬁlms,
especially in the micro electronics industry. The ﬁlm thickness varies greatly from tens
of nanometers [53] to hundreds of micro meters [54]. The spin coating process is a well
documented and well established technique. The process is described here, though for
further details on theory the reader is referred to [55] [56]. Figure 2.5 shows the spin
coating process. First, a solution is dispensed on the center of a substrate. The substrate
is then rotated at high rotation per minute (RPM). The centrifugal force pushes the
solution from the center to the edge of the substrate, where excess solution is spun oﬀ the
substrate. The thickness of the ﬁlm is inversely proportional to the spin speed and time.
After spinning the ﬁlm is dried. The subsequent procedure after spin coating is highly
dependent on the spun solution. It might be drying at room temperature or baking at
elevated temperature. This is highly dependent on the solvent(s) used in the spin coated
solution. Furthermore, heating steps can be used to facilitate cross linking. In our case,
the ﬁlms are either degassed at room temperature or on a hotplate, depending on the
solution and the wanted ﬁlm adhesion. The procedure can be repeated to stack layers of
spin coated ﬁlms on top of each other. Experiments with diﬀerent solutions and spin
Figure 2.5: Main process steps in the spin coating process. [57] First, solution is applied
to the substrate. Then the substrate is rotated. The rotation distributes the solution
uniformly on the substrate creating a ﬁlm. After rotation the ﬁlm is dried. The process
can be repeated to stack layers.
speed are performed to obtain spin curves relating spin speed to ﬁlm height. Figure 2.6
shows the spin curves for solutions of PLLA with a weight percent (wt%) of 25 and 30 and
for a PCL solution with a wt% of 25. The solvent used in both cases is DCM. The spin
time is kept constant at 50 sec. It is seen that PCL and PLLA have similar spin curves.
The 30 wt% solution is diﬃcult to spin and often an uneven result is obtained, hence the
large error bars. Figure 2.7 shows spin curves for a solution of PLLA with a wt% of 15
and 20. The spin curves shown in ﬁgure 2.6 are made with the ﬁrst batch of polymers
received, while the spin curves in ﬁgure 2.7 are made with the second batch of polymers
received. There is a small diﬀerence in the thickness of the polymer ﬁlms created with
the two batches. A 20 wt% solution with the second batch produces almost similar ﬁlm
thicknesses as a 25 wt% solution of the ﬁrst batch. The reason for this is unknown though
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Figure 2.6: Graph showing spin curves for PLLA and PCL solutions in DCM. Solutions
with a polymer weight percent of 25 and 30 are tested. It is seen that the PCL and PLLA
have similar spin curves for similar weight percent solution.
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Figure 2.7: The ﬁgure shows spin curves for PLLA in DCM. Solutions with a polymer
weight percent of 15 and 20 are tested.
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it is likely due to a diﬀerence in molecular weight. The spin curves serve as a guideline for
polymer ﬁlm fabrication. The polymer ﬁlm is later used to fabricate micro containers by
hot embossing, see chapter 5.
2.4.2 PLLA ﬁlm on silicon wafer - procedure
This paragraph describes the procedure used for a successful spin coating of PLLA. Fur-
thermore, the possible post spinning treatments that can be used to tune the adhesion of
the polymer to the substrate are explained.
In order to reproduce ﬁlm thickness and to get a uniform and smooth surface it is rec-
ommended to use fresh solutions every time and not to use the last 10% of solution. The
reason for this is that some of the solvent will evaporate from the solution when using
it and thus the solution will thicken. The wafer should be rotating while the solution is
dispensed on the wafer. When the silicon wafer is coated, the wafer is left to degas for 24
H. This is done in order to minimize the content of solvent left in the ﬁlm. If the wafer is
heated right after spin coating, bubbles of trapped solvent will create a very uneven sur-
face. Depending on the desired adhesion, the following steps can vary. If a good adhesion
is wanted, the wafers should receive a heat treatment. The wafers should be heated on a
hotplate at 220 ◦C for a minimum of 15 min. When removing the wafers, they should be
placed on a poor heat conductor i.e. cleanroom paper. If the temperature decreases to
fast, stress will be induced in the ﬁlm from the diﬀerence in thermal expansion between
the substrate and polymer. This can cause peeling of the polymer ﬁlm. If the PLLA ﬁlm
contains bubbles these can be removed by extending the heating time to i.e. 1 hour. A
weak adhesion of the ﬁlm to the silicon wafer is obtained by not heating the substrate.
If left for several days up to weeks, the adhesion will diminish and result in the polymer
pealing oﬀ. This can be a desired option if you want to release the ﬁlm from the substrate
after complete processing.
2.5 Summary
In this chapter Hansen’s theory of solubility is introduced. Examples of its use to choose
a solvent for PCL are shown and its applications in multiple component systems are de-
scribed. The two biodegradable polymers (PCL, PLLA) mainly used in the project are
introduced along with their properties. It is shown how to prepare ﬁlms, by dissolving the
polymers in organic solvent and spin coating the solutions on silicon substrates. Further-
more, the polymer ﬁlm adhesion to the substrate can be tuned by heat treatment after
spin coating.
Chapter 3
Polymer drug matrix
The idea is to have a versatile ﬁlm consisting of polymer and drug, that is applicable
to many applications such as ﬁlling of micro containers, see section 6.1. This chapter
describes the development of the polymer drug matrix used in the project for ﬁlling of
micro containers via a hot embossing technique. The polymer drug matrix is developed
with the following conditions in mind; 1) The furosemide should preferably be in the
amorphous state, to facilitate a fast dissolution of the otherwise poorly soluble drug. 2)
The matrix should contain as much drug as possible, thus maximizing the amount of active
ingredient per volume. 3) The distribution of the polymer and drug should be uniform.
First, an overview of the solvent-polymer-drug interaction is presented along with the
two methods used for fabricating polymer drug ﬁlms; solvent casting and spin coating.
Second, the developed polymer drug matrix is characterized. The drug dissolution from
the polymer drug matrix is characterized with a Pion μ dissolution UV proﬁler and the
results from these experiments can be found in the drug release chapter 7.
3.1 Solvent-polymer-drug interaction
To achieve the properties above, it is of great importance to understand the interaction of
the polymer, the drug and the solvents, as it aﬀects the ﬁnal product as well as the possible
methods of fabrication. To achieve a homogenous ﬁlm a good blend of the polymer and the
drug is needed. Two diﬀerent techniques are tested for the fabrication of the drug matrix;
solvent casting and spin coating. Other techniques for fabricating ﬁlms exist such as mold-
ing, thermoforming and extrusion, but these have not been investigated in this project.
Hot melt extrusion is widely used in the plastic industry as well as the pharmaceutical
industry and is a good example of how to mass produce polymer drug ﬁlms [58, 59].
Two approaches for achieving a homogenous distribution of polymer and drug have been
considered. 1) Either the polymer and drug should be miscible and thus phase separation
can be avoided. 2) The solvent should evaporate immediately upon ﬁlm formation, thus
freezing the material in place, similar to quench cooling. The ﬁrst approach requires that
the materials are miscible. According to HSP this means that they should be alike, thus
having similar HSP values. The second requirement is that they can be dissolved in the
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Table 3.1: Table of HSP values for selected solvents, polymers and model drug furosemide.
All values are from the HSP database 3.1.2 [45] unless otherwise noted in the table. Note
that the database is constantly updated and values might change.
Material δd δp δh R Dist. Furo Dist furo ﬁt
Furosemide 20.6 12.6 12.9 0
Furosemide ﬁt calc.a 16.92 13.41 8.66 4.5 0
PCL 17.7 5.0 8.4 8.0 10.57 8.56
PLA 18.6 9.9 6.0 10.7 8.42 5.54
Acrylic acid b 11.33 8.08 5.22 20.57 12.85
DCM 17.3 8.2 8.8 8.88 5.27
DMSO 18.4 16.4 10.2 6.41 4.48
Acetone 15.5 10.4 7.0 11.99 4.46
a Calculated HSP values for furosemide based on own experiments, (DCM
DMSO Acetone, isopropanol, ethanol,(water))
b HSP Values from [60]
Table 3.2: Table showing solvent composition for dissolution of selected materials in so-
lutions of DCM/DMSO and DCM/Acetone. The table shows the optimal composition of
solvents based on HSP calculations for the speciﬁc solvents and materials as well as the
optimal composition based on lab tests. The numbers are given in volume.
Material Solvent composition for dissolution
DCM / DMSO DCM / Acetone
HSP optimization
Furosemide 14/86 0/100
PLLA 71/29 100/0
PCL 100/0 100/0
PAA 99/1 1/99 a
Lab tests
PAA + furosemide 32/68 N/A
PCL + furosemide 50/50 50/50 - 25/75
PLLA + furosemide 70/30 - 50/50 a N/A
a Denotes poor solubility
b Lower than 70% dcm = Dissolve only smaller amounts of
PLLA
3.1. SOLVENT-POLYMER-DRUG INTERACTION 21
same solvent, thus their solubility radii must have shared volume in HSP space. Looking
at the HSP parameters for furosemide and polymers in table 3.1, all three polymer have a
greater distance between them and furosemide than the solubility radius R. This is equal
to a RED number above one, meaning that they are not alike. Based on the HSP values
phase separation of the materials is expected. Therefore, the ﬁrst option is unlikely and
the second option is considered for the fabrication of a homogenous ﬁlm. HSP is used to
determine if the drug and polymer can be dissolved in the same solution. To be dissolved
in the same solution the solubility spheres of the compounds must overlap and thus share
a volume in Hansen space. This case is described in section 2.1.4 of the polymer theory.
A blend of solvents is used in order to dissolve both furosemide and polymer. Table 3.2
shows solvent composition for dissolution of the frequently used materials in this project
in blends of DCM/Dimethyl sulfoxide (DMSO) and DCM/Acetone. The table shows the
optimal composition of solvents based on HSP calculations for the speciﬁc solvents and
materials as well as the optimal composition based on lab experience.
Based on the HSP knowledge gathered, solutions containing furosemide and polymers
are developed, especially with PCL as it is easy to work with in terms of molding. The
melting point of furosemide is 203-206 ◦C [61]. The low melting point of PCL (60 ◦C)
enables the furosemide PCL compound to be shaped while the furosemide remains intact.
Experiments involving both solvent casting and spin coating have been conducted. Based
upon initial experiments, spin coating gives the best results. For solvent casting either
phase separation and/or rough surfaces are observed. Furthermore, it is diﬃcult to obtain
ﬁlms in order of tens of microns in thickness. Generally, thicker ﬁlms are produced by
solvent casting. Due to these circumstances it was decided to focus on development of
spin coated polymer drug ﬁlms. Figure 3.1 shows three images of spin coated solutions
with diﬀerent ratios of furosemide to PCL and with diﬀerent blends of DMSO, DCM and
acetone. The main guidelines for mixing of solvents are shown in table 3.2 for furosemide
and the polymer PCL, PAA and PLLA. Figure 3.1(a) shows a ﬁlm where DCM, DMSO
and acetone are used as solvents. The solution consists of 20 ml acetone, 10 ml DCM, 5 ml
DMSO, 2 g furosemide and 3 g PCL. DMSO evaporates slowly while DCM and acetone
evaporate fast. This results in the PCL going fast out of solution while the furosemide
remains in solution in the DMSO. The furosemide concentrates at the top of the ﬁlm result-
ing in an inhomogeneous ﬁlm. Figure 3.1(b) and ﬁgure 3.1(c) show two ﬁlms where DCM
and acetone are used as solvents. The ﬁlm shown in ﬁgure 3.1(b) is clearly inhomogeneous
and exhibits phase separation while the ﬁlm shown in ﬁgure 3.1(c) is homogeneous. The
diﬀerence in the ﬁlms is clearly visible, although the solutions are only slightly diﬀerent.
The solutions consist of the following ratios between acetone:DCM, furosemide:PCL and
combined weight procent of furosemide and PCL. Solution of 3:1, 1:3 and 16.2 wt% for
ﬁgure 3.1(b) and 2:1, 1:4 and 17.2 wt% for ﬁgure 3.1(c). The diﬀerence in acetone to
DCM ratio is a consequence of the diﬀerence in the amount of furosemide for the solutions
and is needed in order to properly dissolve all the furosemide. The solutions used for spin
coating of ﬁlms are summarized in table 3.3.
The ﬁlm shown in ﬁgure 3.1(c) represents the highest amount of furosemide achieved
in a PCL ﬁlm while still having a homogeneous material. The solution used for the ﬁlm
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Table 3.3: Table showing the solutions used for the spin coating of ﬁlms shown in ﬁgure
3.1.
Figure Solvents [ml] Furosemide [g] PCL [g]
3.1(a) DCM/DMSO/Acetone
20/10/5
2 3
3.1(b) DCM/Acetone
10/30
1.5 4.5
3.1(c) DCM/Acetone
10/20
1 4
(a) (b) (c)
Figure 3.1: The ﬁgure shows three images of spin coated solutions containing furosemide
and polycaprolactone. a) shows a ﬁlm where DCM, DMSO and acetone are used as
solvents. DMSO evaporates slowly while DCM and acetone evaporate fast. This results
in the PCL quickly going out of solution while the furosemide remains in solution in the
DMSO. The furosemide concentrates at the top of the ﬁlm in a highly non uniform ﬁlm. b)
and c) show two ﬁlms where DCM and acetone is used as solvent. The ratio of furosemide
to PCL is 1:3 for b) with a 16.2 wt% solution, while it is 1:4 for c) with a 17.2 wt%
solution. The ﬁlm shown in b) exhibits clear phase separation while the materials are well
distributed in c).
shown in ﬁgure 3.1(c) has been used for ﬁlling of micro containers. Figure 3.2 shows an
example of a PCL furosemide blend, where the amount of furosemide is higher than 20
%. While it is possible to achieve a relatively homogenous ﬁlm by spin coating, heating
of the polymer ﬁlm results in spherulites formation. If the furosemide precipitates out of
the PCL matrix forming spherulites or if the PCL forms spherulites is uncertain. There
are two situations that likely can occur; 1) the furosemide acts as a ﬁller in the polymer
and thus the furosemide acts as a nucleation site for the formation of PCL spherulites. 2)
the furosemide forms crystals when heated to 100 ◦C and thus furosemide precipitates out
of drug matrix. The ﬁrst case has not been observed for PCL furosemide ﬁlms with 20%
furosemide or less, which suggest that the second case is observed.
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(a) 5 min heating (b) 10 min heating (c) 15 min heating
Figure 3.2: Optical microscope images of spin coated solution of furosemide and poly-
caprolactone. Column (a), (b) and (c) shows ﬁlms that have been annealed on a hotplate
at 100 ◦C for 5,10 and 15 minutes respectively. The top row shows images right after
the annealing. The middle row 1 day after annealing and the bottom row 7 days after
annealing.
3.2 Drug matrix characterization
A set of experiments based on the optimized polymer drug matrix seen in ﬁgure 3.1(c) is
conducted. A total of six diﬀerent batches are used to evaluate the eﬀect of heat treatment
(Room temperature, 60 ◦C for 10,30,60 min, 100 ◦C for 60 min.) and pressure treatment
(embossing 60 ◦C for 60 min at 1.9MPa) on the drug release and conformation of the
polymer- drug ﬁlms. The objective is to evaluate the stability of the PCL furosemide drug
matrix during processing. This section will describe the experiment and all the results
except for the drug release which is covered in chapter 7.
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(a) (b)
Figure 3.3: The ﬁgure shows spin coatings of a solution consisting of 2 g of furosemide, 8 g
of PCL, 40 ml of acetone and 20 ml of DCM on silicon wafer. It illustrates the importance
of dispensing the solution in the center of the wafer and in a swift manner. a) shows an
unsuccessful attempt while b) shows a successful spin coating process.
3.2.1 Experiment and Methods
The polymer-drug ﬁlms are fabricated by spin coating of a solution consisting of 2g of
furosemide, 8g of PCL, 40ml of acetone and 20ml of DCM on silicon wafers with a ﬂuo-
rocarbon anti-sticking coating [62]. The polymer-drug solution is dispensed on the silicon
wafers rotating at 200 RPM. The wafers are then accelerated at 2000 RPM/s to rotate
at 1000 RPM for 60 s. The resulting ﬁlm thickness is 15 μm measured after 48 hours of
degassing in a fume hood. Thicker ﬁlms can be fabricated by repeating the spin coating
process. Figure 3.3 shows silicon wafers spin coated as described above. The solution
dispensing needs to be swift and precise in the center of the wafer. Otherwise, the spin
coating results in an inhomogeneous ﬁlm as shown in ﬁgure 3.3(a). If the spin coating is
performed properly, the result is a smooth and homogeneous ﬁlm with a slightly opaque
look as seen in ﬁgure 3.3(b). The heating of the ﬁlms is done using a hotplate and the
subsequent cooling is done by placing them on a metal table at room temperature. The
ﬁlms reach room temperature within a few seconds. The ﬁlms are heated to 60 ◦C for
periods of 10, 30 and 60 min and to 100 ◦C for 1 hour. The pressure is applied using an
EVG NIL imprinter capable of exerting a pressure of 1.9 MPa. The ﬁlms are pressed for
60 min at 1.9 MPa at a temperature of 60 ◦C. For characterization, the ﬁlms are cut into
discs with a diameter of 9 mm using a carbon dioxide laser. For ease of handling the ﬁlms
are placed on carbon pads (Agar scientiﬁc, carbon tabs). The polymer drug morphology is
studied by optical images and x-ray diﬀraction. For the x-ray diﬀraction an X’Pert PRO
X-ray diﬀractometer (PANalytical, Almelo, The Netherlands) is used with the following
settings; 45 kV; 40 mA, starting angle of 5◦2θ and an end angle of 35◦2θ.
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(c) (d)
Figure 3.4: Optical images at 50x magniﬁcation showing the drug matrix. a) with no
treatment, it is seen that the ﬁlm is porous. b) with 60 ◦C for 1 hour, still with porous
structures. c) embossed at 60 ◦C, 1.9 MPa for 1 hour, ﬁlm without porous and a smooth
surface. d) heated at 100 ◦C for 1 hour, ﬁlm without porous and a smooth surface.
3.2.2 Results and discussion
A total of six diﬀerent batches are used to test the eﬀect of heat and pressure treatment
on the morphology of the polymer- drug ﬁlms. Figure 3.4 shows optical inspection by
microscope with a magniﬁcation of 50 times. Figure 3.4(a) shows the fabricated ﬁlm
without any treatment. Figure 3.4(b) shows the ﬁlm after annealing at 60 ◦C for 1 hour.
Figure 3.4(c) shows the ﬁlm after embossing at 60 ◦C for 1 hour with a pressure of 1.9MPa.
Figure 3.4(d) shows the ﬁlm after annealing at 100 ◦C for 1 hour. The ﬁgures reveal that
the ﬁlm contains porous structures with a pore size around 5-10 μm after spin coating.
The experiments show that it is possible to remove the porous structure by embossing or
annealing of the ﬁlm above the melting point of the polymer. Heating at 60 ◦C does not
remove or reduce the porous structures while heating at 100 ◦C does. The ﬁlm changes
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Figure 3.5: Graph showing the x-ray diﬀraction data obtained for; crystalline furosemide,
spray dried amorphous furosemide, a spin coated PCL ﬁlm and the spin coated drug
matrix. Both the drug matrix and PCL ﬁlm have a carbon pad as support substrate for
handling. The curves are oﬀset for a clear peak visualization.
color when heat treated. The untreated ﬁlm appears blue due to the blue wafer substrate,
whereas the heat treated ﬁlms occur more opaque. The optical images show that grain
boundaries become more apparent after annealing and this change in the polymer structure
can account for the change in optical appearance.
The morphology of the furosemide and polycaprolactone is studied using X-ray diﬀraction
(XRD). Figure 3.5 shows the XRD spectra of crystalline and amorphous furosemide powder
along with the pure polymer ﬁlm and the drug matrix. The amorphous furosemide does
not show any characteristic peaks, as expected. The crystalline furosemide shows ﬁve
characteristic peaks at 19.26◦, 21.74◦, 23.3◦, 25.18◦, and 29.05◦. This matches well with
other reported data on crystalline furosemide [63, 61], though with a slight upward shift
in the 2θ angle. The most distinct peak (nr. 4) is reported at 24.7◦-24.8◦and is found at
25.18◦in ﬁgure 3.5. The PCL ﬁlm shows two peaks at 21.56◦and 23.89◦. This matches
the peaks reported for semi crystalline PCL at 21.4◦and 23.6◦[64]. The PCL furosemide
drug matrix shows two peaks matching the peaks found for PCL exactly. This shows
that furosemide is in an amorphous state after the drug matrix is spin coated. A reason
for this could be that the spin coating process acts as a quenching of the furosemide and
thus hinders crystallization. Figure 3.6(a) shows the XRD curves obtained for the samples
that are embossed and heat treated at 60 ◦C. The spectra obtained show peaks at the
characteristic semi-crystalline PCL peaks as observed with the non treated ﬁlm. It seems
that the heat treatment at 60 ◦C does not aﬀect the morphology of the drug matrix.
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Figure 3.6: Graphs showing the x-ray diﬀraction data obtained for diﬀerent treatments of
the drug matrix. Drug matrix samples heated on a hotplate at; 60 ◦C for 10,30,60 minutes,
100 ◦C for 60 minutes and embossed at 60 ◦C for 60 min at 1.9 MPa. The non treated
drug matrix is plotted as reference. The curves are oﬀset for a clear peak visualization.
This corresponds to the observations made with the optical microscopy inspection. The
addition of pressure in form of the embossing process does not alter this result. Figure
3.6(b) shows the spectra obtained for the sample heated at 100 ◦C. An additional peak at
25.01 is observed. The peak matches well with the most pronounced peak observed for the
crystalline furosemide in ﬁgure 3.5. It is likely that the elevated temperature facilitates
the formation of crystalline furosemide in the drug matrix. Crystallization of amorphous
furosemide is reported to occur at temperature 80-100 ◦C [63]. The results obtained from
the XRD and the microscopy suggest that the furosemide is amorphous and that it does
not change during processing with temperature of 60 ◦C. For processing at temperatures
of 100 ◦C furosemide crystallinity is observed. The results indicate that the morphology
of the furosemide can be tuned by heat treating the drug matrix.
3.3 Summary
On the basis of HSP a polymer drug matrix is developed. The matrix consists of furosemide
and PCL. The compounds are dissolved in organic solvents, DCM and Acetone to form
a solution which can be spin coated to form ﬁlms. For fabrication of a homogeneous ﬁlm
the highest possible content of furosemide in PCL is 20%. If the content of furosemide
is higher, there is a high risk of phase separation during spin coating. X-ray diﬀraction
shows that the furosemide is in amorphous form after spin coating and remains in this form
after heat- and pressure treatments at 60 ◦C. For heat treatments at 100 ◦C crystalline
furosemide is observed.
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Chapter 4
Stamps
This chapter covers all the stamps fabricated in this project, from fabrication process to
durability. Many stamps have been fabricated in the project in three diﬀerent materials,
SU-8, silicon and nickel. First, the fabrication processes are described along with the
design, then a comparison of the stamps is given along with recommendations. The
development of deep reactive ion etches (DRIE) enabling the fabrication of nickel and
silicon stamps is then described.
4.1 Fabrication
The following sections contain a description of the processes used for fabricating stamps
while the detailed process ﬂows for each stamp fabrication can be found in appendix G,
H, I. The stamps are fabricated at the DTU Danchip cleanroom facilities. The techniques
used for the fabrication are; photolithography, wet and dry etching, metal deposition by
evaporation and sputtering, electro plating, cutting and dicing. For knowledge on theory
and principles of the techniques the reader is referred to [55, 65, 56].
4.1.1 Design
The design of the stamp is based on previous experience with nano imprint lithography
(NIL) and work carried out in the Nanoprobes group, where NIL was used to fabricate
arrays of polymer cantilever chips [66]. The stamps are to be used in a hot embossing
process of thick polymer ﬁlms. The less material that needs to be displaced in order to
obtain the wanted shape, the faster the embossing will be. For this reason it is chosen
to have the stamp structures ”stick out” of the stamp surface, as this will result in the
least amount of material displaced in the hot embossing process. For information on the
hot embossing technique the reader is referred to [67]. Figure 4.1 shows the stamp design.
The stamp is divided in 16 squares, each square with 20 by 20 individual units. With each
square containing 400 units, the total amount of units is 6400. Thus the stamp design
enable the fabrication of 6400 containers. Figure 4.1(b) shows an individual unit. It
consists of two parts, an inner disc and an outer ring structure. There are three important
parameters for this unit. 1) The diameter of inner disk, which translates into the inner
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(a) Overview (b) Single unit
Figure 4.1: The ﬁgure shows the design layout. a) shows how the 16 squares with the
various design parameters are placed. b) shows a single unit design. 1, the inner diameter
of the micro container, 2, the width of the container wall and 3, the separation distance
of the container to the surrounding polymer ﬁlm.
diameter of a micro container, 2) the distance between the disc and ring structure, which
corresponds to the width of the micro container wall and 3) the outer ring structure, which
is the distance that the micro container is separated from the polymer ﬁlm surrounding
the micro container. This design is referred to as the cookie cutter design. The total width
of the containers is kept constant at 300 μm. The wall thickness is varied 10-20-30-40 μm
and thus the inner diameter varies 220-240-260-280 μm. The separation distance to the
polymer ﬁlm is varied 20-30-40-50 μm. The variations in design are chosen to test how
thin the sidewalls can be while still maintaining their stability and to test if the thickness
of the cookie cutter aﬀect the wall formation.
4.2 SU-8 stamps
SU-8 is a negative epoxy photoresist that is widely used in micro and nanotechnology.
It was originally developed by IBM in 1989 [68]. The SU-8 stamps are fabricated on
silicon wafers, working as a stabilizing support substrate for the SU-8 structures that are
made by photolithography. The main components of the stamp are two thick layers of
SU-8. The thickness of the ﬁrst layer determines the depth of the micro containers, while
the second layer determines the bottom thickness of the micro container. Figure 4.2
shows the major steps in the fabrication of the SU-8 stamps. First, a layer of SU-8 is
spin coated and soft baked on a hotplate. Second, the SU-8 layer is illuminated through
a mask to pattern the SU-8 followed by a post exposure bake on a hotplate. Third, a
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Figure 4.2: Schematic showing the ﬁve major steps in the fabrication of SU-8 stamps. A, a
layer of SU-8 is spin coated and soft baked on a hotplate. B, the SU-8 layer is illuminated
through a mask to pattern the SU-8 followed by a post exposure bake on a hotplate. C,
another layer of SU-8 is spincoated and baked. D, the SU-8 is illuminated again through a
mask to pattern the second SU-8 layer. E, both layers of SU-8 are developed in PGMEA.
(a) (b)
Figure 4.3: SEM images of SU-8 stamps. a) shows a stamp that is overexposed and
where SU-8 residues remain in the trench deﬁning the container wall. b) shows a stamp
fabricated with the optimized process recipe. The result is a well deﬁned structure with
vertical sidewalls.
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second SU-8 layer is spincoated and baked. Fourth, the second SU-8 layer is patterned
by photolithography. Fifth, both layers of SU-8 are developed in propylene glycol methyl
ether acetate (PGMEA). The tricky part of the fabrication is to ﬁnd the right exposure
dose for the SU-8. In the optimal case, the process produces vertical sidewalls which is
a requirement for a successful embossing process. To achieve this, the SU-8 receives a
high exposure dose, to ensure that the lower part of the ﬁlm cross links properly. To
avoid heating of the upper part of the SU-8 ﬁlm, the exposure is done in intervals with
30 s cooling cycles between each exposure. Figure 4.3 shows SEM images of single SU-8
stamp units. Figure 4.3(a) shows a case where the top part of the ﬁrst SU-8 layer received
such a high exposure dose that the inner disk is connected to the outer ring structure.
Small residual structures remain in the trench. Figure 4.3(b) shows the optimized stamp
process, where vertical sidewalls and well deﬁned structures are achieved. The details
of the optimized process are found in appendix G. The unit shown in ﬁgure 4.3(b) has
the following design parameters; 220 μm inner diameter, 40 μm wall thickness, 30 μm
separation distance. It is seen that the actual sizes of the SU-8 structures are larger and
that the SU-8 is overexposed by roughly 4 μm.
4.3 Silicon
Figure 4.4 shows the process for fabricating stamps in silicon wafers. The process is
composed of four main components; deposition and patterning of two layers of masking
material and two subsequent DRIE etches. The process starts by deﬁning the ﬁrst etch
mask in aluminium. Photoresist is spin coated, patterned by positive photolithography
followed by development. An aluminium layer is deposited by e-beam evaporation followed
by a liftoﬀ process to make the ﬁrst etch mask pattern. This is step A-D in ﬁgure 4.4.
The second etch mask is deﬁned in photoresist by a negative photolithography step. Step
E-G show spin coating of photoresist, photolithography and development. The wafer is
now ready for the two etching processes. The depth of the ﬁrst etch determines the height
of the container walls, while the second determines the container bottom thickness. Step
H-I shows the ﬁrst DRIE process and the removal of the photoresist etch mask by plasma
asher. The DRIE process is an anisotropic process that allows for etching in one direction.
This process eﬀectively trims down the wafer except where the etch masks protect the
wafer. By having two etch masks it is possible to obtain two diﬀerent heights for the
structures deﬁning the outline of the container and the inner part of the container. Step J
shows the last DRIE process, where the container bottom thickness is deﬁned. A detailed
process ﬂow can be found in appendix H. Figure 4.5 shows the fabricated silicon stamps.
The unit shown in ﬁgure 4.5(b) has the following design parameters; inner diameter of
220 μm, wall thickness of 40 μm and separation distance of 30 μm. It is seen that the
fabrication of the silicon stamp is within a couple of μm from the design parameters.
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Figure 4.4: Schematic showing the major steps in the fabrication of silicon stamps. A)
Deposition of resist by spin coating. B) Patterning by positive photolithography. C) depo-
sition of aluminium by thermal and e-beam evaporation. D) Lift-oﬀ of excess aluminium.
E) Deposition of resist by spin coating. F-D) Patterning by negative photolithography.
H) Anisotropic etch by DRIE process. I) Removal of photoresist by plasma asher. J)
Anisotropic etch by DRIE process.
(a) (b)
Figure 4.5: SEM images of silicon stamp. a) shows an overview of the stamp with several
units. b) shows a single unit and the measured design parameters.
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Figure 4.6: Schematic showing the major steps in the fabrication of nickel stamps. A)
Deposition of resist by spin coating. B) Patterning by negative photolithography. C)
deposition of aluminium by thermal and e-beam evaporation. D) Lift-oﬀ of excess alu-
minium. E) Deposition of resist by spin coating. F) Patterning by negative photolithog-
raphy. G) Anisotropic etch by DRIE process. H) Removal of photoresist by plasma asher.
I) Anisotropic etch by DRIE process. J) Deposition of gold by sputtering. K) Electro
plating of nickel. L) Silicon removal by KOH etching.
4.4 Nickel
The fabrication of nickel stamps resembles the fabrication of the silicon stamps, as it
includes two etch masks and two DRIE steps. The diﬀerence is that the silicon acts as
a mold rather than as the stamp itself. For this reason the structures are etched into
the substrate instead of sticking out. Once the silicon mold is fabricated a seed layer is
deposited on the entire surface of the mold and nickel is electro plated on top of it. The
mold is then removed by etching it.
Figure 4.6 shows the entire nickel stamp process. First, the aluminium etch mask is
deposited and patterned by photolithography of a photoresist followed by a liftoﬀ process,
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step A-D. Second, the photoresist mask is spun and patterned by photolithography, step
E-F. Third, DRIE process and removal of photoresist etch mask, step G-H. Fourth, second
DRIE process. The silicon mold is now complete and the electro plating of the nickel can
start. A gold seed layer is sputtered on the entire mold surface and the mold is submerged
in a nickel plating bath, step J-K. Once the electro plating is complete, the wafer is rinsed
in water and submerged into a KOH bath, where the silicon is etched away. Occasionally,
a heightened edge arises from the electro plating process which is removed by cutting away
the outer 1 cm of the nickel stamp. This marks the end of the fabrication and the stamp
is ready for use after rinse in water.
4.5 Stamp comparison
As described stamps in three materials, SU-8, silicon and nickel are produced. SU-8
stamps are good for prototyping as they are fast to produce and many can be produced
rapidly with a simple photolithography process. The downside of the SU-8 stamps are
that they quickly build up a signiﬁcant amount of ﬂaws during the embossing process.
This can for example be delamination of single or multiple units during the release of the
stamp after embossing or minor deformations. The addition of an anti-sticking coating
only provides a minor prolongation of the lifetime of the SU-8 stamps. Adding a thin
SU-8 layer below the two layers containing the structures decreases the delamination of
structures. Generally, the SU-8 stamps can be used for 5-10 experiments. Silicon is a
strong material and is widely used for stamps in the NIL industry. The fabrication of
the silicon stamps is longer than for SU-8 and not as suitable for a large production as
it contains several single wafer processes. Especially the deposition of aluminium and
the DRIE processes are time consuming. Unfortunately, the silicon stamps turned out
to be very fragile and cracking of stamps during the separation of stamp and embossed
ﬁlm occurred frequently, contrary to expectations. The reason for the cracking is believed
to be caused by the relative large amount of silicon removed during the DRIE process,
exposing defects and/or creating them in the silicon wafer. Cracking of the silicon wafers
is not observed for the support wafers used for the SU-8 stamps and thus the processing
of the silicon must weaken the strength of the material. Due to the cracking problem,
the silicon stamps perform poorly and can generally only be used for 1-2 experiments.
A better and stronger solution than both the silicon and the SU-8 is desired for stable
and repeatable container embossing process. For this reason the attention is turned to
nickel which is a very strong material without the brittle properties of silicon. It is used in
industry for replication of DVD’s among other processes requiring a very high throughput
and thus durability. It incorporates well in the developed silicon technology used for the
silicon stamp and nickel can be deposited / grown by electroplating on a seed layer. The
fabrication process of a nickel stamp resembles the silicon stamp process with an extra
deposition of a seed layer followed by electro plating and removal of the silicon mold. Thus
the process is more time consuming, though the ﬁnal result is a highly durable stamp with
precision of silicon fabrication technology. The strength of the nickel stamps depends on
the speed of the electro plating process. The slower the deposition of nickel is, the more
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Table 4.1: Comparison of SU-8, silicon and nickel stamps. Precision denotes deviation of
the actual fabricated structures from the mask design.
Material Precision Fabrication time Anti-sticking coating Durability
SU-8 +4 μm < 1 week Minimal improvement < 5-10 experiments
Silicon +2 μm < 2 weeks Minimal improvement < 2 experiments
Nickel +3 μm < 3 weeks Not needed >50 experiments
dense and stiﬀ the nickel will be. The deposition of 500 μm nickel can be done in 4 hours,
though it is recommended to do this over a 12-24 hours period to achieve a denser and
more stiﬀ nickel. This lowers the risk of stamp deformation in the ﬁnal cutting process.
The nickel stamps fabricated remain without noteworthy faults after many embossing
experiments. Table 4.1 summarizes the three diﬀerent stamp materials and their respective
performances. The precision describes the diﬀerence between fabricated structure size and
mask design. Some of the processes will inevitably result in a diﬀerent size than that of
the mask design and is by no means a measure of a bad process. The information provides
a basis to design structures of desired dimensions if one are to follow the given processes.
The fabrication time provides a realistic time frame for fabrication of the stamps at the
Danchip cleanroom facilities. Faster fabrication is possible, though delays often occur
due to machine use and service. Anti-sticking coatings developed by Keller et al. [62]
and from a ”Applied Microstructures MVD 100 system” are tested for the SU-8 and
silicon stamps. The coatings improve the separation process after embossing, but do not
extend the lifetime of the stamps signiﬁcantly. The durability summarizes the number of
experiments that one can expect from the given stamps. For the nickel stamp this number
could very well be signiﬁcantly higher as no faults are observed after extensive use. For
hot embossing experiments similar to the ones performed in this project with thick ﬁlms it
is advised to use nickel stamps as they are the most robust stamps and can be fabricated
with the same precision as the silicon and SU-8 stamps.
4.6 DRIE process development
The deep reactive ion etch processes used in the stamp fabrication are important for the
functionallity of the stamps. The etch must produce structures where the sidewall is either
vertical or with a slope that allows the stamp to be separated from the embossed polymer
ﬁlm without compressing the polymer in the separation. Figure 4.7 shows a graphical
representation of this. Figure 4.7(a) shows a situation where separation of the stamp is
easy, as the tips of the stamp are narrower than the base structure. Figure 4.7(b) shows
the opposite situation where the tips are wider than the base structure. To separate
the stamp from the ﬁlm, the ﬁlm will be compressed during separation or the ﬁlm will
rupture if separation is even possible. Situation (a) is referred to as positive sidewall
slope and situation (b) as negative sidewall slope. Two DRIE processes are developed
to accommodate positively sloped sidewalls. The standard mode of operation for DRIE
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(a) (b)
Figure 4.7: a) shows an example of sloped sidewalls on a stamp that allows for separation.
b) shows and example of sloped sidewalls acting as hooks, not allowing for separation.
Table 4.2: DRIE process parameters used in the SPTS Pegasus DRIE tool at Danchip to
obtain positively sloped sidewalls. Dep denotes the passivation deposition and etch denotes
the etching cycle for the Bosch process. - denotes parameters changing throughout the
process with the start and the end value. The Bosch process is run at 0 ◦C while the
continuous process is run at 10 ◦C.
Process Name Mode Pressure Coil/Platen Power Gas ﬂow Cycle time
[mTorr] [W] [sccm] [s]
JNA-D4 Bosch dep 20 dep 2000 / 0 C4F8 : 150 dep 2
etch 26 etch 2500 / 35 SF6 : 275 etch 2.4
O2 : 5
Stamp etch Continuous 230-90 2800 / 170-215 SF6 : 180 N/A
O2 : 160
Ar : 160
tools at Danchip are bosch processes 1 where time multiplexed etching alternates between
two modes. One mode where an isotropic etch removes silicon and another mode where a
passivation layer is deposited. The passivation layer is repeatedly removed in the bottom
by ion etching/bombardment, while the passivation on the sidewalls remains intact. In
this way an anisotropic etch is achieved. In collaboration with Danchip a Bosch process
is developed to achieve positively sloped sidewalls on a SPTS Pegasus DRIE etch tool.
The optimized Bosch process parameters are shown in table 4.2 along with a continuous
process developed at a later stage. First, a description of the Bosch process is given with
focus on the fabricated silicon structures used as molds for nickel stamps.
Figure 4.8 shows the structures produced with the Bosch DRIE process (JNA-D4). Figure
4.8(a) and ﬁgure 4.8(b) show reoccurring fabrication issues. Silicon pillars appear in the
regions where the silicon is supposed to be etched away. The silicon pillars are believed to
be an artifact of relatively equal ratio of etching to passivation time. Figure 4.8(c) shows a
cross sectional view of a silicon mold broken approximately along the center. It is seen that
the sidewalls are vertical in the upper part while they are positively sloped in the bottom.
Increasing the etching cycle time produces vertical to slightly negatively sloped sidewalls.
1Process developed and patented by Robert Bosch GmbH i.e. United States Patent 6531068 and
United States Patent 5501893 among others.
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(a) (b)
(c)
Figure 4.8: The ﬁgure shows SEM images after the second DRIE process in the fabrication
of a silicon mold for electroplating of the nickel stamps. a) and b) shows typical issues
observed after the DRIE process. a) shows sparsely scattered silicon pillars. b) shows
silicon pillars mainly along the side of the deep trench. c) shows a cross-sectional view of
a unit with the following design dimensions, inner diameter 240 μm, wall width 30 μm,
separation distance 50 μm.
As the silicon pillars have a large surface area they are easy to remove in an isotropic wet
polysilicon etch. Figure 4.9 shows the etching of the same pillars at 0, 7 and 15 minutes
of etch time. If the DRIE process produces profound scallops a trick to remove these
is to oxidize the silicon and subsequently remove the silicon oxide. This will smoothen
the surface. Using the Bosch process, well functioning nickel stamps are produced and
used extensively. The process however has some drawbacks as shown in ﬁgures 4.8, 4.9
and a new DRIE process is developed. The new DRIE process does not utilize the Bosch
concept. It is a continuous etch inspired by Li et al. [69] where DRIE etched via holes for
three dimensional MEMS packaging are investigated. The optimized process parameters
are listed in table 4.2 and ﬁgure 4.10 shows some of the results of the optimization. The
process is run at a varying pressure. It starts as high as machine tolerances allow at 230
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(a) (b) (c)
Figure 4.9: The ﬁgure shows SEM images of the same spot on a wafer after isotropic
silicon etch for a) 0 minutes, b) 7 minutes, c) 15 minutes.
(a) Oxide mask (b) Photoresist masking
Figure 4.10: SEM images comparing the results of etching with an oxide mask and a
photoresist mask.
mTorr and is then decreased to 90 mTorr linearly for the duration of the process. The coil
power is kept constant at 2800 W while the platen power is varied linearly 170-215 W. The
linear variations create positively sloped sidewalls as shown in ﬁgure 4.10(a). Figure 4.10
shows the diﬀerence between the use of a hard masking material such as aluminium and
oxide and the use of photoresist as masking material when etching for an extensive period
of time. Photoresist as masking material only works for short periods of etching and is
successfully used for fabrication of stamps following the process described for the nickel
stamp. Figure 4.11 shows a silicon mold fabricated with the continuous DRIE process.
Figure 4.11(a) shows a silicon mold and ﬁgure 4.11(b) shows a zoom of the wall of that
silicon mold. It is clear that the wall has a positive slope. Furthermore, no silicon pillars
are produced with this DRIE process. Figure 4.11(c) shows a confocal microscopy scan
of a silicon mold and ﬁgure 4.11(d) shows the data measured from that scan. The ﬁgures
clearly show the container structure and the measurement shows that the height of the
container is 87 μm with a bottom thicknees of 13-14 μm. Figure 4.12(a) shows the mask
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(d)
Figure 4.11: The ﬁgure shows SEM images of a silicon mold fabricated with the stamp
etch process and a confocal microscopy scan of a silicon mold and the data obtained. It
is seen that the sidewalls are positively sloped. The confocal microscopy scan shows that
the bottom thickness of the container is roughly 13-14 μm and that the reservoir depth is
73-74 μm.
(a) (b)
Figure 4.12: The ﬁgure shows a mask design and a SEM image of a silicon wafer etched
with the continues DRIE process. a) the mask design consists of squares of 300 μm by
300 μm. b) shows a cross-sectional view of a wafer broken along one of the etch lines.
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design consisting of squares of 300 μm by 300 μm. Figure 4.12(b) shows a cross-sectional
view of a wafer broken along one of the etch lines. The depth of the etch is 58 μm with a
width at the top of 39 μm and a width at the bottom of 26 μm. If vertical is considered 90
◦and a positive slope is less than 90 ◦, the slope of the sidewall in ﬁgure 4.12(b) is around
77-78 ◦.
4.7 summary
Processes for the fabrication of stamps in SU-8, silicon and nickel have been presented.
SU-8 is found to be suited for fast prototyping with the shortest fabrication time of the
three materials, while nickel by far is the most durable and the preferred material for
stamps used for extensive experiments. The only drawback of the nickel stamp compared
to the SU-8 and silicon is the more time consuming fabrication process. The fabricated
silicon stamps performed poorly and are not recommended for experiments similar to the
ones performed in this project. It is believed that the brittle nature of silicon is the main
cause for concern. DRIE processes producing sloped sidewalls for better release of stamps
are developed. It is found that the slope of the sidewalls can be controlled by varying the
pressure and platen power.
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Chapter 5
Micro containers
This chapter covers the diﬀerent micro containers fabricated in this project. First, the
SU-8 container fabrication is described along with examples of diﬀerent container designs.
A short review of possible fabrication technologies is given along with arguments of why
technologies are chosen or discarded. Then the micro containers fabricated in the FDA
approved biopolymers polycaprolactone and polylactide acid [70] are described along with
the hot embossing process used to do so.
5.1 SU-8 micro containers
The ﬁrst prototypes of the micro containers are fabricated in the photosensitive epoxy
resist SU-8. The process resembles the one described for the fabrication of SU-8 stamps in
section 4.2. Figure 5.1 shows the fabrication process. A layer of SU-8 is spin coated on a
silicon wafer and baked. The layer is then patterned by photolithography. The thickness
of this layer deﬁnes the bottom thickness of the micro containers. A second layer of SU-8
is spin coated and patterned by photolithography. The thickness of this layer deﬁnes the
height of the micro container walls. The patterning of the container in the two SU-8 lay-
ers is now complete and the SU-8 is developed in propylene glycol methyl ether acetate.
The development removes the non exposed SU-8 leaving behind the micro containers on
a silicon wafer. The exact process details for the containers are described in appendix
F. Micro containers with diﬀerent design parameters are fabricated to meet experiment
criteria and to showcase diﬀerent possibilities. The most used design is containers with an
outer diameter of 300 μm and an inner diameter of 200-260, thus varying the wall thickness
from 20-50 μm. The height of the fabricated containers is varied as well and containers
with a total height ranging 85-300 μm are realized. The SU-8 micro container process is
a very ﬂexible process and various geometries can be fabricated with it. Figure 5.2 shows
some of the possibilities of the process. Figure 5.2(a) shows micro containers with four
diﬀerent diameters of 50,100,150,300 μm and multiple compartments in the case of the
squared containers with compartments sizes of 20,40,60,120 μm. As seen in the ﬁgure
the three largest container sizes are mechanically stable, while the smallest container is
leaning a bit. Figure 5.2(b) shows containers with a diameter of 300 μm and varying wall
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Figure 5.1: Schematic showing the ﬁve major steps for the fabrication of SU-8 micro
containers. A, a layer of SU-8 is spin coated on a silicon wafer. B, the bottom container
layer is exposed. C, another layer of SU-8 is spin coated. D, the container sidewalls are
exposed. E, the redundant SU-8 is removed in propylene glycol methyl ether acetate.
thickness. The wall thickness needs to be thicker than 5 μm for a container to maintain
its stability and avoid buckling. Figure 5.3 shows the typical micro container design
with an outer diameter of 300 μm. The wall thickness of the containers shown is 40 μm
by design although the actual size is slightly larger. The SU-8 prototype containers are
mainly used by collaborators to test various drug delivery aspects involving ﬁlling of micro
containers and spacial conﬁnement of drugs [71] [72]. In this work, SU-8 micro containers
are used to test wafer scale ﬁlling of micro containers with a solid polymer drug matrix
by embossing. This method enables ﬁlling of thousands of micro containers in one process
and is described in section 6.1 and appendix A.
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(a) (b)
Figure 5.2: The ﬁgure shows some of the possibilities of fabricating a variety of diﬀerent
designs with the SU-8 micro container process. a) multiple micro containers with diﬀerent
sizes and design, providing an idea of what is possible. b) circular micro containers with
an outer diameter of 300 μm with varying wall thickness.
(a) (b)
Figure 5.3: The ﬁgure shows the typical SU-8 micro container design. a) overview of micro
containers with an outer diameter of 300 μm. b) close up view of the containers seen in
a).
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5.2 Biodegradable polymer containers
Micro fabrication in FDA approved biopolymers presents a challenge compared with con-
ventional micro fabrication where often photo-resists are used to pattern materials via
diﬀerent methods of pattern transfer or the resist itself is used to create structures. An
example of this is the SU-8 micro container fabrication presented above or the stamp
fabrication presented in chapter 4. No commercial FDA approved biodegradable polymer
resins exist on the market today and thus the use of photolithography to fabricate micro
containers directly is not possible. Researchers are looking into developing such materials
i.e. A˚kesson et al. study resins based on lactic acid and soybeans [73], while Pulkkinen et
al. study cross linking of PCL based resins [74] [75]. A short review of possible fabrication
technologies is given below. An introduction to hot embossing is given as this is the most
used technique for container fabrication. Containers fabricated in PLLA and PCL are
presented along with the challenges faced in the fabrication processes.
5.3 Fabrication technologies
Many fabrication techniques for structuring polymers exist today such as thermoforming,
extrusion, molding and casting. Diﬀerent techniques for polymer micro structuring exist,
such as micro milling, injection molding, etching, three dimensional printing, laser cutting,
two photon laser writing and embossing. The diﬀerent techniques all have their strengths
and weaknesses and a short review of these are given in the following paragraphs.
Micro milling In micro milling ﬁne tools are used to remove material in a ﬁlm or a sheet.
Tools with a typical feature sizes of 100 μm are commercially available and structures with
feature sizes of roughly 100 μm can be fabricated. Tools with a width of tens of microns
have been used in recent years, thus pushing the limits for fabrication[76]. The technique
is good for prototyping and it is not suitable for mass production as each part needs to
be milled.
Two photon laser writing Two photon laser writing is used in micro- and nano tech-
nology for fabricating three dimensional structures for several diﬀerent applications such as
scaﬀolds, tissue engineering, molds etc [77]. The technique is very good for fabrication of
true three dimensional structures and there are basically no limitations to the design. The
drawbacks are that a limited number of resin materials are available for this techniques
and that the process requires long writing times.
Injection molding Injection molding is a very common method for fabrication of poly-
mer structures. Well know products made this way are the lego
TM
toys. The technique
is great for mass fabrication though the drawback is that it is diﬃcult to fabricate struc-
tures with thin features like the walls and the bottom of the micro containers. A batch
of containers is fabricated by injection molding in polypropylene at collaborators at DTU
Mechanics. Figure 5.4 shows some of the injection molded structures lined up next to each
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(a) (b)
Figure 5.4: The ﬁgure shows two images of the injection molded micro containers. It is
seen that the containers consist of a thick bottom layer with ring structures on top.
other as well as a close up. The injection molded structures form a thick base with ring
structures of varying sizes on top. The diameter of the ring structures are roughly 500 μm.
The fabrication showed that injection molding is not suitable for container fabrication but
it can be used for a model system with a thick bottom layer.
Etching Etching as a fabrication method for containers is considered and initial steps
are taken to develop this method. Speciﬁcally DRIE processes are in development and
these are used in the project for diﬀerent purposes. The advantage of using etching as
fabrication method is that many containers can be made at once. Drawbacks include loss
of precision, rough surfaces, need for masking methods.
Laser cutting Laser cutting of polymers is used in the project for cutting out polymer
ﬁlms and for initial experiments on container fabrication in PLLA ﬁlm. Figure 5.5 shows
a micro container fabricated in a PLLA ﬁlm. The advantages of laser cutting are that the
process is fast, it is very ﬂexible and allows for fast design changes. Drawbacks include
local heating of material and possible generation of radicals during the processing.
Hot embossing Hot embossing is an old and well known technique for patterning of
polymers i.e. a wax seal. In micro and nanotechnology the similar process of nano imprint
lithography is used for fabrication of structures ranging from nm to μm. The advantages
of hot embossing are that high precision can be obtained and that large surfaces can be
structured in one process. The disadvantages include a residual layer that needs to be
removed afterwards for separation of structures and the need for a stamp. The technique
is useful for 2.5d structures with the restraint that the stamp needs to be removed.
Roll to roll The roll to roll technique is well known and used for many diﬀerent purposes
such as electrodes [78] and polymer solar cells [79]. The technique is very good for mass
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Figure 5.5: Optical image of a micro container made by laser cutting of a PLLA ﬁlm. The
image show the light reﬂecting of the sloped sidewalls of the container.
production and a good candidate for commercialization of micro containers. The drawback
is that large quantities of material are required for the development of a working process.
5.4 Comparison of methods
When deciding which fabrication method to go with it is important to keep in mind what
the potential volume of containers is and what requirements one has to the dimensions of
the containers. In the case of the model drug furosemide, a dose of 20 mg - 40 mg is common
for the treatment of edema. If a 20 mg furosemide dose is to ﬁt inside containers without
any excipient the following amount of containers are needed, assuming a cylindrical shape
with an inner diamter of 200 μm and a height of 100 μm.
# containers =
0.020g · 1.6 g
cm3
π · (0.01cm)2 · 0.01cm ≈ 10000 containers (5.1)
With a need for thousands of containers some of the fabrication methods can be elim-
inated. Two photon laser writing as well as micro milling do not oﬀer an acceptable
volume production. Etching could be possible though several aspect of this technique re-
main uncertain. As for laser writing and embossing, both techniques oﬀer medium volume
production and are possible condidates. Roll to roll and injection molding are both high
volume production techniques. Roll to roll facilities are not accessible to the Nanoprobes
group and thus this technique has not been explored. Injection molding is possible though
initial experiments showed extensive challenges to overcome with respect to size and pre-
cision of container production and thus this method is discarded. This leaves embossing
and laser cutting as candidates. Embossing is chosen as the main fabrication method as
this technique oﬀers medium production and high precision fabrication. Laser cutting
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equipment in form of CO2-lasers are accessible and experiments using this to fabricate
containers have been performed. The experiments showed that a fast output is possi-
ble though with very limited precision and with possible issues with high temperature
processing. For these reasons hot embossing serves as the main fabrication method of
biodegradable micro containers. For future fabrication, roll to roll is deﬁnitely a possi-
bility as well as laser writing in terms of recent development within laser machining in
transparent materials [80].
5.5 Hot embossing
The hot embossing technique utilizes a drop in material stiﬀness when exceeding what
is known as the glass transition temperature (Tg). Figure 5.6 shows a schematic of the
embossing process. Figure 5.6(a) shows a curve explaining the eﬀect of young’s modulus
as a function of temperature for polymers. Below the Tg the polymer is stiﬀ and remains
in its current conﬁguration. Once the temperature passes the Tg, the polymer chains
can move with respect to each other. With the ability of chain movement the material
becomes softer and rubber like. If the temperature is increased further the melting point
Tm is reached and the polymer becomes molten allowing free ﬂow of the polymer chains.
The plateau between Tg and Tm is known as the rubbery state of the polymer. In this
state it is possible to shape the polymer by applying pressure on it. The hot embossing
technique utilizes this material characteristics. A stamp is brought in contact with the
polymer. The polymer is then heated above the glass transition temperature, going from
1 to 2 in ﬁgure 5.6(a). Pressure is then applied to the stamp, forcing it into the polymer.
Once the stamp is fully pressed into the polymer, the polymer is cooled below the Tg,
going from 2 to 1 in ﬁgure 5.6(a). In this way the polymer stiﬀens while retaining its
current shape. The stamp is ﬁnally separated from the polymer. Figure 5.6(b) shows
(a) (b)
Figure 5.6: The ﬁgure shows a graphics of the young’s modulus as a function of temper-
ature and a graphics showing the component of a hot embossing process after a stamp is
release from a polymer ﬁlm.
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an illustration of a stamp after embossing and separation of the stamp from the polymer
layer. The structures on the stamp can either stick out of the surface or be grooved in
the surface. In this case the structures are sticking out of the surface. The reason is that
less materials needs to be move in the embossing process. The less material that needs to
be displaced in order to obtain the wanted shape, the quicker the embossing will be. The
entire process is often run in vacuum to avoid trapping of air bubbles, which can result in
poor pattern transfer. For theory on hot embossing the reader is referred to [67].
5.6 PLLA containers
For the fabrication of the PLLA containers embossing as described above is used. The
Tg of PLLA is around 60
◦C, see table 2.2, and thus embossing is carried out above this
temperature. Figure 5.7 shows the result of an experiment where embossing at 80, 100
and 120 ◦C is carried out. For the experiment, SU-8 stamps are used and similar results
are observed for the nickel stamps. Other embossing parameters such as time, pressure
and ramping are kept constant at 1 hour, 1.9 MPa, 10 ◦C/min. The graph shows the
measured container wall height after embossing and the corresponding stamp height. The
ﬁgure shows that embossing with these parameters results in partial pattern transfer for
80 and 100 ◦C while a good pattern transfer is obtained at 120 ◦C. The study is published
in Microelectronic Engineering and can be found in appendix B. Figure 5.8 shows a PLLA
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Figure 5.7: The ﬁgure shows the measured wall height after embossing in PLLA polymer
ﬁlm. The blue, green and red curves show the results of embossing at 80, 100 and 120 ◦C
respectively. The black line shows the corresponding stamp height.
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container after embossing and a schematic with a cross sectional view of a container. The
container is covered with a thin layer of gold for better SEM imaging. The embossing
(a) (b)
Figure 5.8: Hot embossed micro container in PLLA with gold thin ﬁlm for SEM imaging
and a schematic of the cross sectional view of a container. The dimensions of the micro-
container are; Outer diameter of 300 μm, inner diameter of 240 μm, height of 100 μm,
wall height of 65 μm.
process leaves a residual layer behind connecting the container to the redundant polymer
ﬁlm. To release the containers from the polymer ﬁlm it needs to be removed or broken. It
is desirable to release all of the containers from the polymer ﬁlm in one process. A possible
solution is to etch the residual layer with an oxygen plasma [81]. In collaboration with
Danchip investigations on polymer etching are conducted. The etching is performed in a
DRIE machine though less than optimal results are achieved for the structured containers.
During the etching the PLLA is only partially removed and meshes of residues are left
behind. Furthermore, the etching process primarily attacks the top of the PLLA structure
and thus the bottom of the separation trench is not attacked as strongly. The longer the
etching is sustained the more pronounced the eﬀect become. Figure 5.9 shows the result
of prolonged etching for 24 minutes. It is clear that the etching is non uniform and that
it is not an anisotropic etch, which would be the ideal scenario. Development of DRIE for
polymers such as PLLA and PCL is an ongoing task at Danchip and could be a solution
in the future. As of now the process is not working as intended.
Besides the removal of the residual layer the polymer needs to be separated from the
wafer. This can be done in several ways. The adhesion can be tuned in the spin coating
process and thus enable the polymer ﬁlm to be peeled oﬀ. Another trick is to put water
at the edge of the wafer. Once the water comes in contact with both the polymer and the
wafer, it is drawn in between the polymer and wafer, due to capillary forces. The water
eﬀectively separates the polymer ﬁlm from the wafer. Another and similar approach used
in the project is to spin coat a thin layer of PAA before spin coating the PLLA on top.
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(a) (b)
Figure 5.9: PLLA micro container etched for 24 min and a zoom of that surface.
(a) (b)
Figure 5.10: Pictures showing the long term eﬀect of crystallization during the hot em-
bossing process if the ﬁlm containing the micro containers is kept on the silicon substrates.
a) PLLA ﬁlm embossed at 100 ◦C. b) PLLA ﬁlm embossed at 120 ◦C.
The PAA is water soluble and dipping the wafer in water after the embossing results in
a lift-oﬀ of the polymer ﬁlm. The same approach is successful with the use of dextran
and other researchers have used this technique with a variety of materials [82]. A side
eﬀect of the embossing process is that the PLLA increases its crystallinity. The growth
in crystallinity happens when the polymer is heated to 120-160 ◦C according to Abe et
al. [83]. Figure 5.10 shows two wafers with containers in PLLA, one embossed at 100 ◦C
and one at 120 ◦C. The wafers have been stored in the Danchip cleanroom at a constant
temperature of 20 ◦C and relative humidity of 45 % for six months. The sample embossed
at 100 ◦C retains good adhesion to the wafer and show no polymer cracking. The sample
embossed at 120 ◦C is delaminated and cracks have propagated throughout the polymer
ﬁlm. The cracking of the embossed PLLA ﬁlm can be avoided by releasing the ﬁlm from
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Figure 5.11: The ﬁgure shows the measured wall height after embossing in PCL polymer
ﬁlm. The red and the blue line shows the results of embossing at 60 and 55 ◦C respectively.
The black line shows the corresponding stamp height.
the substrate within a few weeks of fabrication. The methods described above are used
for the release and once the ﬁlm is lifted from the substrate, no cracking is observed for
prolonged storage times at room temperature.
5.7 PCL containers
Embossing in PCL is a special case since the Tg is -60
◦C and the Tm is 60 ◦C. PCL
is ”rubbery” at room temperature and thus embossing at room temperature should be
possible. The material however is diﬃcult to emboss and with the embossing tool available
at DTU danchip it is not possible to go above 1.9 MPa in pressure. At this pressure it
is not possible to perform embossing at room temperature and little to no deformation of
PCL appears. Therefore it is decided to emboss at a temperature just below the melting
point as this should lead to a lower Young’s modulus of the PCL. Figure 5.11 shows
the container wall height at three points between the center and the edge of the stamp.
The black line shows the corresponding height of the stamp and the red and blue lines
show the container wall height for embossing experiments done at 55 and 60 ◦C for 1
hour at maximum pressure of 1.9 MPa. It is seen that embossing at 60 ◦C results in
a good pattern transfer matching the stamp dimensions. Embossing at 55 ◦C results
in a partial pattern transfer where the wall height is signiﬁcantly lower than the stamp
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(a) (b)
Figure 5.12: PCL hot embossed micro containers. a) Embossed at 60 ◦C with a ramping
of 10 ◦C / min. The embossing results in a diﬃcult separation of the stamp and the
PCL ﬁlm. The separation tears the container walls apart. b) Successful pattern transfer
achieved at 60 ◦C with a ramping 5 ◦C / min. The temperature does not overshoot and
melt the PCL ﬁlm and an easy separation of the stamp and the ﬁlm ensures a good pattern
transfer.
dimensions. The ramping of temperature for the embossing process is very important due
to the close proximity of the embossing temperature to the melting point. If the ramping
is fast the temperature can overshoot and cause the PCL to melt or partly melt before
the temperature stabilizes at 60 ◦C. If that happens the PCL is either completely stuck
to the stamp or the PCL is torn during separation of the stamp. Figure 5.12 shows PCL
containers embossed at 60 ◦C after stamp separation. In ﬁgure 5.12(a) the ramping is 10
◦C/min while it is only 5 ◦C/min in ﬁgure 5.12(b). It is clear that the container walls
are elongated in the stamp separation process in ﬁgure 5.12(a) when compared to the
successful pattern transfer observed in ﬁgure 5.12(b). Thus for a successful embossing in
PCL, the ramping should not exceed 5 ◦C/min. To remove the residual layer in the case
of PCL containers, similar approaches and unfortunately similar results as for the PLLA
are observed. Alternatively, the containers can be released by laser cutting although the
current setup of laser cutters does not support alignment.
5.8 Summary
Micro containers in SU-8, PCL and PLLA have been fabricated. The SU-8 containers are
realized by a photolithography process while the PCL and PLLA containers are realized
by hot embossing in spin coated PCL and PLLA ﬁlms. Embossing tests showed that a
good pattern transfer is obtained at 120 ◦C for PLLA and at 60 ◦C for PCL. Residual
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polymer layer left after the embossing process is diﬃcult to remove in an eﬃcient manner
and development is needed to successfully achieve this task.
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Chapter 6
Container ﬁlling
In this chapter three experiments dealing with ﬁlling of micro containers are described.
First, a hot embossing process for ﬁlling of micro containers is shown. This method is used
in the project to ﬁll micro containers in SU-8. This work was presented at the 16th interna-
tional conference on miniaturized systems for chemistry and life sciences, μTAS 2012 and
a three page conference proceeding can be found in appendix A. Second, a method using
a simple form of screen printing for ﬁlling of micro containers is described. This method
was used in the project to ﬁll micro containers of the biodegradable polymers PLLA and
PCL. Third, solvent casting is described as a possible ﬁlling method. This method is in
development and has so far not been used for further micro container experiments. Other
methods, such as inkjet printing and CO2 impregnation, are investigated in the NAMEC
project by colleagues and will not be covered here.
6.1 Embossing
This section describes a method developed in order to ﬁll micro containers on wafer scale
with a solid polymer drug matrix. For the experiment, SU-8 micro containers as the ones
shown in section 5.1 are used. As solid polymer drug matrix, the ﬁlms described in section
3.2 are used.
6.1.1 Process
Figure 6.1 shows a graphical representation of the process while ﬁgure 6.2 shows SEM
images after the major process steps. The two starting components are the SU-8 containers
shown in ﬁgure 6.2(a) and the polymer drug matrix, see section 3.2, on a silicon wafer
substrate coated with a ﬂuorocarbon anti-sticking coating [62]. The polymer-drug ﬁlm
is embossed into the micro containers at a temperature of 60 ◦C and a pressure of 1.9
MPa for 1 hour, ﬁgure 2.1. Embossing at 60 ◦C, which is just below the melting point of
PCL, ensures an optimal hot embossing and pattern transfer. The system is then cooled
to 20 ◦C and the silicon wafer initially holding the drug matrix is removed, as shown
in ﬁgure 6.2(b). The anti-sticking coating ensures that separation takes place between
the coating and the polymer-drug ﬁlm. A deep reactive ion etch is used to separate
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Figure 6.1: Schematic of the micro container ﬁlling process using hot embossing of a
polymer drug matrix. The starting point are micro containers on a silicon substrate and
a polymer drug matrix on a silicon substrate with an anti-sticking coating, a) and b).
The polymer drug matrix is embossed into the containers and the following separation
occurs between the anti-sticking coating and the polymer drug matrix, c) and d). A deep
reactive ion etch is performed to trim down the polymer drug matrix. This separate
the drug matrix in the containers from that outside the containers e). The containers
are released from the substrate by peeling the redundant drug matrix and mechanically
removing the containers, f).
the micro containers from the excess polymer-drug matrix, shown in ﬁgure 6.2(c). The
etching is performed with an advanced silicon etcher using the following parameters for an
anisotropic etch. O2 ﬂow of 20 sccm, Ar ﬂow 20 sccm, platen power 150 W, coil power 600
W, pressure 4 mTorr, temperature 10 ◦C and time 12 min. The etching process has been
developed in collaboration with Danchip personnel. The process uses an oxygen plasma
coupled with a high platen and coil power to remove the polymer. The high power results
in some sputtering of the drug matrix. However the high power is needed for the process to
remove signiﬁcant amount of material. Finally, the containers are mechanically released,
as shown in ﬁgure 6.2(d). The containers can be lifted from the substrate by scraping or
with tweezers. The adhesion of the containers to the substrate is very poor, probably due
to the heating and cooling involved in the etching process.
6.1.2 Result & discussion
The result of the embossing process is SU-8 micro containers ﬁlled with a ﬁlm consisting of
polycaprolactone and furosemide, as shown in ﬁgure 6.2. The method is demonstrated to
work on wafer scale level with 4 inch wafers. The containers can be lifted from the substrate
by scraping or with a pair of tweezers. It is however very diﬃcult to handle the individual
containers and subsequently place them. The release of the containers is a delicate process
as they tend to stick to anything they come in contact with. Figure 6.3 shows some of
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(a) (b)
(c) (d)
Figure 6.2: The ﬁgure shows images before, during and after the ﬁlling process shown in
ﬁgure 6.1. a) SU-8 micro containers before the process. b) Polymer drug matrix after
embossing and separation from the substrate. c) Filled micro containers after the polymer
drug matrix is trimmed down by DRIE. d) Filled SU-8 container with the polymer drug
matrix after release from the substrate.
the released containers collected in a capsule. The method for ﬁlling containers with a
drug matrix can be applied to diﬀerent systems following a few fabrication requirements.
The Tg of the polymer drug matrix must be lower than the one of the micro container
material. The embossing temperature should be in-between the Tg of the polymer drug
matrix material and the Tg of the micro container material. This ensures a reﬂow of
the polymer drug matrix without aﬀecting the structural stability of the micro containers.
Furthermore, the embossing temperature should not exceed Tm of the components to allow
separation of the embossed stack after the cooling process. The experiment is done with
SU-8 containers as they stick out of the surface and thus present a favorable embossing
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Figure 6.3: The image shows released micro containers collected in a capsule.
case where minimal material needs to be deformed. If the process is to be performed on
the biodegradable polymer containers the situation is very diﬀerent. These containers are
in plane with the redundant polymer. Embossing a ﬁlm into the biodegradable containers
means that the majority of the polymer drug matrix needs to be transferred into the
small voids of the containers. For this to work, the biodegradable containers need to be
separated from the redundant ﬁlm. The separation of biodegradable containers is a process
under development, but for future applications this method could be a possibility since
the temperature needed to emboss PLLA is higher than the 60 ◦C used for the embossing
of the PCL furosemide ﬁlm.
6.2 Screen printing
This section describes a ﬁlling method for containers inspired by traditional screen printing
technique. Screen printing is a technique utilizing a woven mesh in combination with a
stencil mask to form open areas in the woven mesh [84]. A squeegee is used to press a
paste or an ink through the mesh resulting in the stencil pattern being transferred to a
substrate.
6.2.1 Experiment
In this work a simple version of the screen printing technique is applied. A ﬂexible stencil
is fabricated in transparent foil by laser machining and used without the woven mesh. The
laser machining is done with a CO2-laser and the exact process parameters can be found
in appendix J. The design of the stencil is made such that it contains holes matching
the inner diameter of the micro containers with a few microns in variation. A graphical
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Figure 6.4: Graphics showing the ﬁlling process using screen printing, 1 stencil is aligned
to containers, 2-3 furosemide powder is pressed into the containers, 4 stencil is removed.
representation of the ﬁlling process using screen printing is shown in ﬁgure 6.4. First, the
stencil is aligned to the micro containers with an optical microscope (Figure 6.4.1). Then
furosemide powder is pressed through the stencil (Figure 6.4.2, Figure 6.4.3). Finally the
stencil is removed together with any excess powder (Figure 6.4.4).
6.2.2 Result & discussion
Figure 6.5 shows optical images of micro containers in PLLA ﬁlled with furosemide powder
using the technique depicted in ﬁgure 6.4. Figure 6.5(a) shows a single container ﬁlled with
furosemide. A small amount of furosemide resides on top and outside the container wall.
The image is a good representation of how most containers look like in a successful process.
Figure 6.5(b) shows an overview of a process with a slight mismatch in alignment. It is seen
that some furosemide is deposited beside the containers while others have a good ﬁlling
without furosemide beside them. Due to the very ﬂexible transparent foil and fabrication
variations in the stencil it is diﬃcult to achieve a perfect alignment of the stencil to the
containers. This is the cause for the variation in deposition of furosemide powder. Taking
these factors into consideration the method performs quite well with respect to ﬁlling
and it is used in the project for ﬁlling of micro containers with furosemide powder. If
the process is optimized, it is believed that ﬁlling of micro containers without misplaced
material is possible. Introducing a self aligned stencil [85] and a magnetic stencil ensuring
a good clamping of the stencil to the containers [86], perfect ﬁlling of the containers should
be possible. The strength of the process is that the technique can be applied to any of the
micro containers presented in this thesis.
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(a) (b)
Figure 6.5: Micro containers made in PLLA by embossing ﬁlled with furosemide powder.
a) Micro container with 300 μm diameter ﬁlled with furosemide powder. b) Array of
micro containers ﬁlled with furosemide by screen printing. Arrows point at the furosemide
deposited beside the containers.
6.3 Solvent casting
This section deals with the idea of using solvent casting in combination with surface tension
to ﬁll micro containers. In the ﬁeld of microﬂuidics, surface tension is a well know property
used to manipulate ﬂuids [87]. Due to the micrometer size of the containers the idea is
to test if surface tension can be used to ﬁll the containers. The aim is to have solution
stay in the micro container while excess solution can be removed by tilting the substrate.
Figure 6.6 shows a schematic of the idea. Solution is dispensed on the containers and the
substrate is then tilted. The tilting allows excess solution to run oﬀ the substrate while
surface tension keeps the containers ﬁlled. The tricky part is to get the tilting angle right.
The tilting angle should be large enough that excess solution runs oﬀ the substrate and yet
small enough so that solution stays in the micro containers. Ideally, the solution should
act as water on a super hydrophobic surface, allowing the solution to run oﬀ while not
leaving anything behind.
6.3.1 Experiment
For the experiments micro containers in PCL are tested as PCL is known for its hy-
drophobic properties [88] [89]. A solution of furosemide and PAA in DMSO is used in
the experiment. The weight ratio of PAA to furosemide is 2:1 and the total wt% of the
solution is 13.6. DMSO is used as it has a high boiling point and thus a slow evaporation
allowing time to manipulate the solution on the PCL container sample. The solution is
dispensed on the samples. The sample is carefully manipulated so that the solution covers
the entire array of containers. By tilting the sample the solution starts ﬂowing oﬀ the
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Figure 6.6: Schematic of the solvent casting idea. a) and b) solution of PAA and furosemide
is deposited. c) and d) excess solution runs oﬀ the substrate while surface tension keeps
solution in place in the containers.
substrate and the residual solution is collected in a beaker. Small droplets of solution
remain for the majority of the container locations.
6.3.2 Result & discussion
Figure 6.7 shows the results of the experiment. Figures 6.7(a) and 6.7(c) show the con-
tainers before the experiment and ﬁgures 6.7(b) and 6.7(d) show the containers after the
experiment. It is seen that the containers are indeed ﬁlled by this method. Furthermore,
the surface area between the containers is changed, which likely means that some solution
is deposited there as well. Comparing ﬁgures 6.7(a) and 6.7(b) it is seen that only small
amounts of polymer and drug reside in the trench next to the container. The contain-
ers are still well deﬁned and they seem to be completely ﬁlled. To investigate the ﬁlling
further the sample is measured with a Dektak 8 stylus proﬁlometer. Figure 6.8 shows
representative proﬁlometer scans of containers after the experiment. Figure 6.8(a) shows
a case where the container is almost ﬁlled. A small diﬀerence in height of 5-10 μm between
the container wall and reservoir of the container is observed. With a total container height
around 100 μm and a reservoir depth of roughly 65 μm. It can be conclude that around
90 % of the container volume has been ﬁlled. Unfortunately, it is not possible to measure
the depth of the separation trench due to the aspect ratio (narrow and deep) and thus
the shape of the proﬁlometer tip is imaged at the trench ”bottom”. What can be said
about the trench ﬁlling is that it is signiﬁcantly less than the container ﬁlling though an
exact measurement is not obtained. The fact that the trench is not ﬁlled to the same
level as the containers suggests that either the solution only partially enters the trench
or the solution easily escapes the trench in the tilting process. Based on the observations
from the experiment the latter seems to be the most likely scenario. Figure 6.8(b) shows
a case where two containers and the excess polymer ﬁlm between them are proﬁled. It is
seen that the containers are almost completely ﬁlled, with a diﬀerence in height of only a
couple of μm between the wall and the reservoir. It is seen that the excess polymer ﬁlm
between the containers are roughly 10 μm higher than the containers. This measurement
supports the observations on ﬁgure 6.7 that the surface between the containers is altered.
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(a) (b)
(c) (d)
Figure 6.7: The ﬁgure shows SEM images before and after ﬁlling of containers using solvent
casting. a) and c) shows empty PCL containers. b) and d) shows ﬁlled PCL containers.
It is seen that surface in between the containers is altered. It is likely that a thin polymer
drug layer is deposited.
It is likely that a layer of PAA and furosemide is deposited. While the results show that
this method can be used to ﬁll containers, it also shows that a polymer drug ﬁlm is de-
posited everywhere. The fact that the PAA furosemide ﬁlm is both inside and outside the
containers can be solved in diﬀerent ways. If a coating is applied to the containers and not
to the surrounding areas, the excess PAA and furosemide might be washed away while the
coating protects the container with the PAA furosemide inside. This could i.e. be done by
spray coating through a shadow mask [86], a process that is in development by a colleague
in the Nanoprobes group. The solvent casting process might be optimized by introducing
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(a) (b)
Figure 6.8: The ﬁgures shows two proﬁlometer scan of containers after the solvent casting
deposition process. It is seen that the containers are ﬁlled with the solvent casting process.
a partly patterned surface. Altering of the surface can be done by chemical modiﬁcation
[90] or deposition of material. i.e. spray coating. If the surface altering process is done
with a masking material or stencil, speciﬁc areas such as the containers or the areas in
between the containers can be targeted. If the surface is tuned in this manner, it might
be possible to reduce the amount of material deposited in unwanted places.
6.4 Comparison
The three ﬁlling methods described in this chapter have their strengths and weaknesses.
The embossing method is good for ﬁlling a large amount of containers in one process. This
is an important aspect as thousands of containers are needed for a dose of furosemide.
The downside of the method is that it requires the micro containers to be placed on a
surface like the SU-8 containers presented in section 5.1 and that the polymer drug matrix
only contains 20 % drug (at its current stage). The amount of drug might be increased
with further development of the polymer drug matrix or with the use of other polymers
and drugs. The method is not limited to the SU-8 containers and might be feasible if
biodegradable containers are fabricated in a manner that leaves them protruding on top
of a substrate. The PLLA used in this project matches the material conditions described
in the embossing process for a successful ﬁlling process with respect to Tg and Tm. The
screen printing method is used to ﬁll the biodegradable containers. This method is very
versatile as it only requires alignment of the stencil to the containers. Thus the container
material is not important and the process can be used regardless of material preference.
The process provides a high ﬁlling level and completely ﬁlled containers are obtained. The
process is demonstrated on squares with 400 containers. The screen printing process is up
scalable and it is possible to do wafer scale deposition with high precision in the tens of μm
range [91]. The downside of the process is the need for alignment to the containers. The
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Table 6.1: Comparison of the three ﬁlling methods described in the chapter. The table
shows the type of container the three ﬁlling methods have been used for. The level of
ﬁlling obtained and the process level.
Method Container
type
Filling Process level
Embossing SU-8 80% PCL
20% Furosemide
Wafer scale
Screen printing PLLA / PCL up to 100%
Furosemide
400 container square
upscalable process
Solvent casting PCL 66% PAA
33% Furosemide
Wafer scale
solvent casting method presents a simple ﬁlling method for a large amount of containers.
The ﬁlling level of the containers depends on the solution used. In the experiments a
blend of 33 % furosemide and 66 % PAA is used. The process works well on a wafer scale,
though polymer and drug is deposited outside the containers. The container ﬁlling is not
limited to a certain material, however the choice of material is likely to aﬀect the behavior
of the solution. The three methods are summarized in their current development stage
in table 6.1 The table lists the container type for which the processes are developed, the
level of container ﬁlling and the scale of the process. Of the three processes the screen
printing method is the most versatile process as it can be applied to any container shape
and the potential ﬁlling level is 100 %. With further development, as suggested in section
6.2.2, the screen printing method provides a robust method for ﬁlling of micro containers.
The embossing process is a viable alternative to the screen printing process, though with
certain limitations to the ﬁlling level and requirements to container structure. The solvent
casting method needs further development for it to be eﬀective.
6.5 Summary
In this chapter it is shown that it is possible to integrate ﬁlling of micro containers as
part of the fabrication on a wafer scale level through hot embossing of a polymer drug
matrix in SU-8 containers. Filling of micro containers using a screen printing method is
shown to work with furosemide powders, thus utilizing the container volume to its fullest
in respect to the amount of active pharmaceutical ingredient. The method is demonstrated
on PLLA containers, though the method is applicable to SU-8 containers as well. Last,
a method based on surface tension for ﬁlling of the containers is investigated. Filling of
containers is successful however redundant polymer medicine solution is deposited outside
the containers.
Chapter 7
Drug delivery
This chapter covers the method used to test drug release, the results of drug release from
the drug matrix described in chapter 3 and drug release from micro containers described
in chapter 5 are shown. First, a description of the Pion μDISS proﬁler
TM
used to test drug
release is given along with standard procedures used for the drug release experiments.
Once the test method is established, the release data for the drug matrix and the micro
containers are presented. Finally, an experiment using UV imaging to validate drug release
from the micro containers in real time is shown.
7.1 Dissolution
This section covers the test setup used for dissolution testing of the diﬀerent drug delivery
systems developed. To test release of drug a Pion μDISS proﬁler
TM
is used. Figure 7.1
shows the Pion μDISS proﬁler used for the dissolution measurements. The machine is
capable of conducting six release tests simultaneously. The proﬁler is controlled with a
computer which is also used for data collection. Figure 7.2 shows a close up view of the
test setup. It shows the beakers used and the tip of the UV probes. The device uses UV
spectroscopy to measure concentration of a solution over time. The UV probes measure
absorption of the UV light as it passes through solution. The travel distance of the UV
light is twice the distance from the UV probe to the mirror. The longer the travel length
is, the more UV light is absorbed. To avoid full absorption at speciﬁc wavelengths, the
distance from the UV probe to the mirror is adjustable. The beaker contains a combined
magnetic stirrer and sample holder. The magnetic stirrer ensures a good mixing of the
solution. The entire setup is placed inside a water bath to control the temperature of
the solutions. In order to measure the concentration of a compound, standard curves are
made with known concentrations of the compound and the UV absorption is measured. In
this way a correlation between the UV spectrum and the concentration of the solution is
obtained. For the case of the drug matrix and the micro patches the following conditions
are used. The drug release is performed using biorelevant dissolution media, Fasted State
Simulated Intestinal Fluid (FaSSIF), to simulate the gastrointestinal ﬂuids. The FaSSIF
is pH adjusted to pH 6.5 before the release experiments are conducted in beakers contain-
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Figure 7.1: The image shows the Pion μDISS proﬁler used for dissolution experiments. It
is seen that the machine has six separate testing setups consisting of a UV probe that is
inserted in a beaker with solution. The beaker has a sample holder at the bottom which
at the same time functions as a magnetic stirrer.
Figure 7.2: The image shows a close up of the Pion μDISS proﬁler setup. It shows the
tip of the UV probe, the mirror and the beakers with the stirrer in a solution. The stirrer
functions as a sample holder at the same time.
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ing 10 ml FaSSIF media kept at a temperature of 37 ◦C. The magnetic stirrer is set to
100 RPM. In case of the micro containers similar conditions as above are used with the
exception, that dissolution tests at diﬀerent pH are conducted to test the eﬀectiveness of
enteric coatings. For this purpose a combination of Fasted State Simulated Gastric Fluid
(FaSSGF) with a pH of 1.5 and FaSSIF pH 6.5 are used. First, the containers are kept
for 120 minutes in FaSSGF media, and then the media is changed to the FaSSIF in which
the containers are kept for 180 minutes.
7.1.1 Measurement uncertainties
In the dissolution experiments PLLA and PCL polymers are used in connection with
the furosemide model drug. Control experiment with PCL and PLLA are conducted to
investigate whether or not the polymers aﬀect the dissolution tests. Films of pure PCL
and PLLA are tested against the standard curves used for the furosemide dissolution
experiments to see if ”furosemide is released” from the pure polymer ﬁlms. Figure 7.3
shows the dissolution results for PCL and PLLA ﬁlms. It is seen that both polymers show
”release”. The eﬀect of the PCL is higher than that of the PLLA. It can be concluded
that both polymers contribute to the release concentration measured.
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Figure 7.3: Graph showing the release signal from PCL and PLLA.
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7.2 Drug matrix
This section covers the drug release from the drug matrix described in chapter 3. Dis-
solution tests are performed on seven diﬀerent drug matrix batches; samples with a ﬁlm
thickness of 15 and 39 μm, heat treated; 60 ◦C for 10, 30, 60 min and 100 ◦C for 60 min,
embossed at 60 ◦C for 60 min at 1.9MPa are tested.
7.2.1 Release results & discussion
Figure 7.4 shows dissolution curves for drug matrices with a thickness of 15 and 39 μm.
It is seen that the thin drug matrix releases furosemide faster than the thicker ﬁlm, but
the thicker ﬁlm releases more furosemide. The 15 μm thick ﬁlms release most of the
furosemide within 1 hour and then the concentration stabilizes while the 39 μm thick
ﬁlms release furosemide for the duration of the dissolution test. The rate of furosemide
release decreases with time. The concentration approaches a stable level at the end of the
dissolution test. In order to determine how much drug is released from the ﬁlms, the ﬁlms
are weighed before dissolution tests. The weight of the 15 μm thick ﬁlm is 1 mg and the
weight of the 39 μm thick ﬁlms is 3.2 mg. With a blend of 20 % furosemide to PCL, the
amount of furosemide in the 15 μm thick ﬁlms is 0.2 mg and 0.6 mg for the 39 μm thick
ﬁlm. Calculating the amount of released furosemide at the end point of the graphs shown
in ﬁgure 7.4 with respect to the total amount of furosemide in the ﬁlms gives:
10ml · 17.1 μgml
0.2mg
100% = 85.5% ;
10ml · 49.1 μgml
0.604mg
100% = 81.3% (7.1)
The calculation shows that 81-85 % of the furosemide is released from the drug matrix.
Figure 7.5 shows the cumulative release curves for three samples; the non treated, the
embossed and the 60 ◦C, 1 hour heat treated. Furthermore, it shows the release curves
for two furosemide discs, one consisting of amorphous furosemide and one consisting of
crystalline furosemide. It is seen that the embossed and the heat treated samples release
all of the furosemide while the non treated sample only releases about 80-85 % furosemide
as calculated. The fact that the samples go above 100 % release of the furosemide can
be explained by the contribution from the PCL, as observed in ﬁgure 7.3. Furthermore,
there is some uncertainty in weighing samples with such a small weight. An analytical
laboratory balance is used with a precision of ±0.1 mg. The lack of precision can account
for as much as 10% uncertainty as the total weight of the samples varies from 1-3.2 mg.
This uncertainty is not included in the error bars. The graph shows that the release from
the drug matrix is fast and that all the furosemide is released within 30 minutes for the
embossed and heat-treated samples while it takes an hour for the non treated sample. The
release from the drug matrix resembles the quick release observed from the amorphous
furosemide disc, while the release from the crystalline disc is very slow. The embossed and
the heat treated samples have similar release characteristic and thus pressure treatment
does not seem to aﬀect the drug release. Figure 7.6 shows the cumulative release curves
for all the heat treated samples with the non treated sample as reference. It is seen that
the samples with short heating at 60 ◦C and the sample heated at 100 ◦C have a faster
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Figure 7.4: Graph showing the release curves for two diﬀerent thicknesses of the PCL
furosemide drug matrix.
release than the sample heated for 1 hour at 60 ◦C. The fact that the drug release increases
from roughly 80 % to 100 % when the drug matrix is heated is yet to be explained. It can
be concluded that heating results in similar drug release characteristics, whether it be 10
minutes at 60 ◦C or 1 hour at either 60 or 100 ◦C. The spin coating process, which the
drug matrix is fabricated by, resembles a quench cooling of the polymer. It could be that
the quenching traps some of the furosemide in the PCL in such as way that it is not able
to diﬀuse out of the polymer drug matrix. Heating of the drug matrix should increase the
crystallinity of both PCL and furosemide. It is likely that the heating allows the trapped
furosemide to rearrange itself in the drug matrix making it available for release or that
it is forced out by crystal growth. The exact process involved in releasing the trapped
furosemide is unknown at this point. The drug release results show that PCL as a matrix
for furosemide works very well and that it is possible to get all of the furosemide released
from the matrix. Heating and pressure in form of embossing does not hinder release of
furosemide, if anything it enhances the release. This behavior enables the drug matrix to
be processed and thus provides a versatile polymer drug ﬁlm that can be used in various
applications.
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Figure 7.5: Graph showing the cumulative release curves for; the embossed, the non treated
and the 60 ◦C 1 hour treated samples. For comparison release curves for discs made of
crystalline and amorphous furosemide are plotted.
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Figure 7.6: Graph showing the release of the samples with diﬀerent heat treatments
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7.3 Micro containers
This section describes the drug release from the micro containers prepared as summarized
in ﬁgure 7.7. Its shows the micro containers at three diﬀerent stages; container shaping
by embossing, ﬁlling by screen printing and coating by spray coating.
7.3.1 Experiments
Two diﬀerent sets of experiments are conducted. One, PLLA containers ﬁlled with crys-
talline furosemide powder are tested. This corresponds to the situation shown in ﬁgure
7.7(e). The samples used for the experiment are squares of 400 containers. The experiment
is conducted as described in section 7.1. Two, release from coated containers is tested,
(a) Embossing (b) Filing by screen printing (c) Spray coating
(d) Empty containers (e) Filled containers (f) Coated containers
Figure 7.7: PLLA containers at diﬀerent stages.
this corresponds to the sample shown in ﬁgure 7.7(f). Spray dried amorphous furosemide
is used for the experiment. The dissolution tests for the second experiment and the prepa-
ration of the spray dried amorphous furosemide powder are performed by PhD student
Line Hagner Nielsen at the Department of Pharmaceutics and Analytical Chemistry at
the University of Copenhagen. For this experiment FaSSGF media of pH 1.5 and FaSSIF
media of pH 6.5 are used to test the eﬀectiveness of an enteric coating made by spray
coating of Eudragit R© L100 (Evonik industries) on the PLLA containers. The Eudragit R©
L100 is a polymer used by the pharmaceutical industry for coating of tablets. It does not
dissolve in acidic solutions, such as the stomach environment, but it dissolves at higher
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pH present in the intestine. The deposition is made with an ExactaCoat system from
Sono-Tak.
7.3.2 Release results & discussion
First, the results of experiment one are presented, then the results of experiment two are
presented. The results of the ﬁrst dissolution test is shown are ﬁgure 7.8. It is seen that the
furosemide is dissolved fast and a stable concentration level is reached after 5-7 minutes.
After dissolution tests the containers are inspected by microscope. The inspection shows
that no furosemide is left in the containers. The containers are weighed before and after
ﬁlling and the diﬀerence is found to be 2 mg. The graph shows that 180 μg/ml is released
from the containers, corresponding to 1.8 mg released furosemide. A possible explanation
for the diﬀerence in furosemide is loss of furosemide during handling of the samples before
the experiment. The containers are not coated and thus the furosemide is lying loosely in
the containers. The results from the second dissolution experiment with Eudragit coated
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Figure 7.8: Graph showing the release of crystalline furosemide powder from PLLA con-
tainers.
PLLA containers are shown in ﬁgure 7.9. It is seen that the release of furosemide is
neglectable for the ﬁrst 120 minutes where the containers are immersed in FaSSGF media
with a pH of 1.5. Once the media is changed to FaSSIF pH 6.5, the furosemide is released
swiftly. The release curve indicates that the Eudragit coating withstands the FaSSGF
media, while it is dissolved by the FaSSIF media, resulting in release of furosemide. The
containers are inspected after dissolution tests and no furosemide is found to reside on the
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PLLA after the experiment. It is seen that the release curve does not equate to 100 %
dissolution of furosemide. A possible explanation for this is that some of the furosemide
is blown away during the spray coating of Eudragit. The Eudragit polymer is deposited
onto the surface of the containers by a stream of nitrogen gas. The furosemide powder
consists of particles with a size down to 5 μm. It is likely that these particles can be
redistributed by the nitrogen gas stream, either redepositing on the container surface or
removed from sample entirely. Another possibility is that some of the furosemide diﬀuses
into the PLLA instead of dissolving in the FaSSIF media. Based on the HSP data for
PLLA and furosemide presented in table 3.1 the two compounds are not alike. Thus it is
unlikely that furosemide diﬀuses into the PLLA. Finally, the furosemide could enter the
solution as particles, though not dissolve and thus not contribute to the concentration of
the solution. The drug release results from the micro containers show that it is possible
Figure 7.9: Graph showing release curve of furosemide from Eudragit-coated PLLA micro
containers in biorelevant media at pH 1.5 for 120 min and at pH 6.5 for 180 min. Data
represent n=3±SD
to control the release of drug by pH sensitive polymers. It shows that most of the drug
if not all is released from the containers and that the drug release happens within a few
minutes.
7.4 UV imager experiment
This section describes an experiment conducted on PLLA containers that have been ﬁlled
by screen printing and spray coated with an enteric coating of Eudragit L100. The experi-
ment is performed to verify the observation from the dissolution tests. For the experiment
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a test setup (UV imager) available at the Department of Pharmaceutics and Analytical
Chemistry at the University of Copenhagen is used. The UV imager experiment and data
analysis is performed by Post doc. Sarah Gordon.
7.4.1 Experiment
Figure 7.10: Schematic showing the UV imager setup used by Sarah Gordon for the
experiment. [92]
For the experiment, a sample with four containers PLLA containers is cut out by
laser to match a cylindric holder with an inner diameter of 1.5 mm. Figure 7.10 shows
a schematic of the test setup. The setup consists of a syringe pump system, where the
syringes are connected to a ﬂow cell via tubes. A sample holder is located at the bottom of
the ﬂow cell. Around the ﬂow cell, a setup consisting of a pulsed Xenon lamp in connection
with a band pass ﬁlter is located on one side and a UV camera chip is located on the other
side to record UV images. The setup allows for real time imaging of release from the
sample holder in the ﬂow cell. For a more detailed explanation of the measurement setup
the reader is referred to [92, 93]. First, gastric media with pH 1.5 is passed through the
ﬂow cell for 5 minutes to test the enteric coating. Then, intestinal media with pH 6.5 is
passed through the cell until the drug release is complete. The ﬂow rate of both media is
0.2 mL/min.
7.4.2 Results & discussion
The result of the experiment is shown in ﬁgure 7.11, where four images taken at diﬀerent
times are shown. Figure 7.11(a) shows an image after 5 minutes of gastric media. No
release from the containers is observed. Figure 7.11(b) shows an image after 1 minute of
ﬂow with intestinal media. It is seen that furosemide is released from the containers. This
is the starting point of the release. Figure 7.11(c) shows an image after 5 minutes of ﬂow
with intestinal media. At this point the release of furosemide is at its peak. Figure 7.11(d)
shows an image after 15 minute of ﬂow with intestinal media. At this point, the release
7.5. SUMMARY 77
(a) Gastric media, pH 1.6, 5 min ﬂow (b) Intestinal media, pH 6.5, 1 min ﬂow
(c) Intestinal media, pH 6.5, 5 min ﬂow (d) Intestinal media, pH 6.5, 15 min ﬂow
Figure 7.11: The ﬁgure shows images at speciﬁc times for the UV imager experiment.
The sample is placed in the bottom center of the images. Contour Lines: dark blue = 100
mAU, green = 150 mAU, orange = 200 mAU, light blue = 250 mAU, brown = 300 mAU.
mAU = milli-absorbance units.
from the containers is almost complete. The series of images illustrates the drug release
from four containers coated with Eudragit L100. It is observed that it takes less than a
minute for the Eudragit to be dissolved by the intestinal media and that the peak of the
release happens after 5 minutes. At this point the release diminishes and the majority of
the drug is released after 15 minutes. The experiment supports the observations from the
dissolution experiments. The enteric Eudragit coating is dissolved by the FaSSIF media
shortly after it is introduced in the ﬂow cell. The release of the furosemide from the
containers occurs quickly, peaking after 5 minutes whereupon the release slowly decreases.
7.5 Summary
In this chapter methods for characterising drug release from the drug matrix and the con-
tainers are described; dissolution tests using a Pion μDISS proﬁler R© and a setup utilizing
a ﬂow cell in combination with UV imaging equipment. It is found that the drug matrix
releases 80% of the total furosemide contained within the matrix in its initial state. If the
drug matrix is heat treated at 60- or 100 ◦C, the drug matrix releases 100%. Furthermore,
the release time is shortened by the heat treatment. For the micro container drug delivery
systems, the drug release occurs within a few minutes. The release from the container
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system can be controlled by enteric coatings. Experiments show that an Eudragit L100
polymer coating can prevent drug release in acidic media, FaSSGF pH 1.5. Changing the
media to FaSSIF pH 6.5 dissolves the coating and drug release from the container system
is observed. The experiments show that it is possible to tune the release of drug through
coatings.
Chapter 8
Conclusion
The goal of this project has been to develop techniques for micro fabrication in biodegrad-
able polymer and to use these techniques to realize biodegradable micro containers for oral
drug delivery. This has successfully been achieved by fabrication of micro containers for
drug delivery by hot embossing in biodegradable polymer ﬁlms made of PLLA and PCL.
Polymer solutions have been developed using the theory of Hansen’s solubility param-
eters. The solutions are used to deposit ﬁlms which are used in the fabrication of the
micro container. The ﬁlms are made by spin coating and experiments have shown that it
is possible to fabricate uniform and homogeneous PCL and PLLA ﬁlms with a thickness
up to 110 μm. While it is possible to realize thicker ﬁlms, the thickness variation in in-
creases drastically as the ﬁlm thickness increases.
It is found that the adhesion of the PCL and PLLA ﬁlms to silicon substrates can be
tuned by heat treatment following the spin coating process. If a strong adhesion is desired
the heat treatment should exceed the melting temperature of the polymer. Following the
heat treatment, the polymer should be cooled slowly to room temperature to avoid stress
caused by diﬀerences in thermal expansion of polymer and substrate. This procedure can
be used to remove potential bubbles in the polymer ﬁlms. A poor adhesion is obtained by
heat treatment below the melting point or no treatment at all.
Solutions consisting of both polymer and pharmaceuticals have been developed using the
Hansen’s solubility parameters. Drug matrices have been fabricated by spin coating these
solutions. It is found that organic solvents should have similar boiling points and thus
similar evaporation rates if more than one solvent is used. If the evaporation rates diﬀer,
the solvent composition changes with time which can result in precipitation of either poly-
mer or pharmaceutical. Homogenous drug matrices are obtained with solvents having a
low boiling point and thus a fast evaporation rate. A drug matrix consisting of PCL and
furosemide has been developed. It is found that the highest weight ratio of furosemide
to PCL is 1:4 to achieve homogenous ﬁlms. A blend of DCM and Acetone is used in a
volume ratio of 1:2 to dissolve both compounds. Microscopy characterization of the PCL
furosemide matrix has shown that the matrix contains porous structures with a size of
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5-10 μm. Experiments have shown that the porous structures can be removed by heating
above the melting temperature of the polymer or by performing an embossing at 1.9 MPa
above the Tg. The morphology of the drug matrix has been studied by X-ray diﬀrac-
tion and experiments show that furosemide is amorphous after spin coating. Experiments
show that the furosemide remains amorphous after the drug matrix is heat treated at
60◦C and after embossing at 1.9 MPa at 60 ◦C. If the drug matrix is heat treated at
100◦C, the furosemide starts to crystallize. The experiments show that the PCL remains
semi crystalline for all kinds of treatment. Drug release from the drug matrix is tested by
dissolution. Experiments show that the drug matrix releases 80% of the total furosemide
contained within the matrix. If the drug matrix is heat treated at 60 ◦C or 100 ◦C, the
drug matrix releases 100% and the drug release is shortened. Pressure such as the one
applied during embossing has no eﬀect on the drug release.
Hot embossing processes have been developed for fabrication of micro containers with
the biodegradable polymers PCL and PLLA. A stamp is pressed into a spin coated poly-
mer ﬁlm of PCL or PLLA. A successful pattern transfer from stamp to polymer ﬁlm is
achieved at 60 ◦C and a pressure of 1.9 MPa for 1 hour for the PCL ﬁlms. For the PLLA,
a successful pattern transfer is obtained at 120 ◦C and a pressure of 1.9 MPa for 1 hour.
Embossing experiments show that a residual layer connects the micro containers to the
surrounding polymer ﬁlm after embossing and that the residual layer is diﬃcult to remove
in an eﬃcient manner. Crystallization of PLLA is observed during the embossing and to
avoid cracking of the PLLA ﬁlm it should be lifted from the substrate after embossing.
No cracking is observed for the PCL ﬁlm.
For the embossing process, stamps in three diﬀerent materials have been fabricated. SU-8
stamps have been fabricated by a two step photo lithography process. Silicon stamps have
been fabricated by a two step DRIE process. Nickel stamps have been fabricated by a two
step DRIE process followed by an electroplating process. Both silicon and SU-8 stamps
have shown limited durability, with SU-8 having the better performance of the two. The
brittle nature of silicon causes severe damage to the stamps during embossing. For the
SU-8, the lack of durability is believed to be caused by a lack of material strength. The
nickel stamps have shown impeccable durability and are recommended for further work.
DRIE processes capable of producing positively sloped side walls have been developed. It
is found that by varying the chamber pressure and platen power, the slope of the sidewalls
can be controlled. The sloped sidewalls enable an easy release of stamps from polymer
ﬁlms.
Besides the micro containers fabricated in the biodegradable polymers PCL and PLLA,
micro containers have been fabricated in SU-8. The containers are made by a two step
photo lithography process. The SU-8 micro containers serve as a model system for testing
ﬁlling methods for micro containers and initial studies on micro containers as drug delivery
devices.
Three diﬀerent ways of ﬁlling micro containers with drug have been tested; embossing
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of polymer drug matrix, solvent casting and screen printing. The embossing of polymer
drug matrix to ﬁll micro containers has been tested on SU-8 containers. The ﬁlling method
has been shown to work on a wafer scale. The method is not limited to the SU-8 contain-
ers and might be feasible as ﬁlling method for the biodegradable containers, if they are
fabricated in a manner that leaves them sitting out of plane with the polymer ﬁlm. The
drug loading is related to the ratio of drug to polymer used in the drug matrix. At its
current state, this means a ﬁlling level of 20 %. Solvent casting is another method used to
ﬁll micro containers. The method works on a wafer level, although polymer and drug is
deposited outside the micro containers as well as inside. In the experiments a blend of 33
% furosemide and 66 % PAA was used and thus a ﬁlling level of 33 % is currently possible.
Screen printing is another method used to ﬁll micro container and this method is the one
used for drug release experiments carried out with the micro containers. The method
utilizes a stencil fabricated by laser cutting of a transparent foil. The foil is aligned to the
micro containers whereafter the containers are ﬁlled by scraping drug across the stencil.
The foil is removed along with excess drug. If pure drug powder is used, the method allows
for up to 100 % ﬁlling level. The method is tested on squares containing 400 biodegradable
micro containers. The method is not limited to the biodegradable containers and can be
used for the SU-8 containers as well. The method is up scalable and is recommended for
ﬁlling of micro containers.
Drug release experiments with furosemide showed that release from the micro contain-
ers take place within a few minutes and that most of the furosemide is able to exit the
container and dissolve in simulated intestinal media. It is shown that the drug release of
the containers can be controlled by adding polymeric coatings. Experiments show that an
Eudragit L100 polymer coating prevents drug release in simulated gastric media, pH 1.5
while it dissolves in simulated intestinal media, pH 6.5 and enables drug release from the
containers.
In conclusion micro systems for drug delivery have been developed. To achieve this, poly-
mer ﬁlms have been fabricated by spin coating of solutions consisting of PCL and PLLA
in organic solvents. Deﬁning of micro structures by hot embossing processes has been de-
veloped. The processes enable large scale fabrication of micro containers in biodegradable
polymers. Large scale ﬁlling methods have been developed for the biodegradable micro
containers. Enclosed micro container drug delivery devices capable of releasing drug by
change in pH have been demonstrated by spray coating of enteric coatings. A drug matrix
has been developed by spin coating solutions consisting of both polymer and drug.
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Chapter 9
Outlook
Micro containers present progress towards the vision described in section 1.1 further im-
provements are needed. Separating containers and handling of individual devices has
proven to be diﬃcult. Therefore imminent improvements within these areas are needed.
A possibility is to use laser machining equipment to fabricate the entire device or to cut
out the micro containers after embossing. Another option is to introduce a sacriﬁcial layer
on which the micro containers can be fabricated. The sacriﬁcial layer can then be cut into
pieces containing a desired amount of containers needed for a dose. Once the containers
need to be released, this can be done by dissolving the sacriﬁcial layer. One possibility is
to use a water soluble polymer layer, like the PAA used in this work.
At this stage, the drug matrix consists of a polymer and a drug that are not alike ac-
cording to HSP. The principle of the HSP is that ”like dissolve like”, thus it could be
interesting to match polymers and drugs by HSP values. This could be a way to increase
the amount of drug that can be homogeneously distributed in the polymer ﬁlm. Another
possibility is to investigate if the introduction of surfactants to the drug matrix could
increase the drug loading.
A lot of research has been put into the development of micro devices for oral drug delivery,
as detailed in section 1.5 and in this work. It has shown that a large number of devices,
thousands to hundred thousands, are needed for the delivery of a dose. Thus, fabrication
of these devices needs to be up scaled to accommodate this. It means that fabrication
techniques capable of fabricating millions, if not billions are needed. Additionally, the
micro devices have to be able to compete with other drug delivery systems such as con-
ventional tablets and pills. This means that the fabrication must be cheap. These factors
point in the direction of mass production.
The state of art of micro devices for oral drug delivery is as follows; proof of concept
has been shown for; protection of drug by container and outer layers, mucoadhesion by
surface chemistry modiﬁcation or polymeric coatings, controlled release by enteric coat-
ings and unidirectional release by design. To advance the concept of micro devices for oral
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drug delivery the following needs to be accomplished; clinical trials where micro devices
are used for treatment and where features (drug protection, mucoadhesion, unidirectional
release) of micro devices proves critical for the success of the treatment. Furthermore,
fabrication techniques enabling mass production of devices are crucial; large amounts of
devices are needed for a dose and many doses are needed in order to conduct clinical trials.
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MICRO CONTAINERS WITH SOLID POLYMER DRUG MATRIX FOR 
ORAL DRUG DELIVERY 
Johan Nagstrup1, Stephan Sylvest Keller1, Anette Müllertz2 and Anja Boisen1 
1Technical University of Denmark, DTU Nanotech, Denmark 
2University of Copenhagen, Department of Pharmacy, Denmark 
 
ABSTRACT 
In this work, we present micro containers for drug delivery and a method for wafer scale filling utilizing hot 
embossing. Hot embossing of a polymer drug matrix followed by a deep reactive ion etch (DRIE) enables filling and 
release of individual micro containers. Finally, drug release from the embossed polymer drug matrix is shown.     
 
KEYWORDS Drug delivery, Hot embossing, micro container. 
 
INTRODUCTION 
Advances in microtechnology and pharmaceutical engineering have led to the proposition of micro containers as 
carriers for oral drug delivery [1] [2] [3]. Micro containers can be used for oral administration and are able to protect 
drug from degradation during transit of the gastro-intestinal tract. Further they will enable one-directional drug release at 
the site of absorption and can thereby enhance the bioavailability of drugs. 
Traditionally, micro containers are filled by micro spotting or microinjection [2]. The techniques require liquid 
solutions and are time consuming. Alternatively, micro containers are filled using hydrogels, a batch method involving 
several process steps such as deposition, cross-linking, washing, and swelling [2] [3]. Our method enables an easy 
integration of filling of solid drug formulations into micro container during the fabrication process.  
 
THEORY 
Hot embossing is a technique by which an amorphous or semi-crystalline material is molded with a stamp to achieve 
a wanted shape. Hot embossing is possible due to lowering of the Young’s moduli of materials when the temperature 
approaches the melting point, Tm. The point where the softening sets is known as the glass transition temperature, Tg. The 
glass transition is a reversible transition from a hard state into a molten state. Hot embossing takes advantage of that 
reversible process by molding the material above the Tg and below the Tm. A stamp is used to mold the material in the 
desired shape by pressing the stamp in the material. Once the stamp is filled with material, the system is cooled below the 
Tg, thus hardening the material before the stamp is withdrawn.  
 
EXPERIMENTAL 
The micro containers are fabricated in SU-8 by a two step photolithography process using a silicon wafer as substrate, 
as shown in figure 1. The micro containers have an outer diameter of 300 μm and an inner diameter of 200-250 (design 
variation). The total height is measured to be 105±5μm with a container depth of 60±5μm. The polymer-drug film is 
fabricated by spin coating of a solution of polycaprolactone (PCL) and furosemide (furosemide is a diuretic drug used for 
the treatment of e.g. edema) on a silicon wafer with a fluorocarbon anti-sticking coating [4]. The solution consists of 20 
ml dichloromethane, 40 ml acetone, 8 g PCL, 2 g furosemide. The spin coating parameters are 1000 rpm for 60 s with a 
ramp of 2000 rpm/s. The resulting film is 15 μm thick. To achieve the desired thickness of 45 μm, the spin coating 
procedure is performed 3 times. 
Figure 2 shows the major process steps in the micro container filling. First, the polymer-drug film is embossed into 
the micro containers at a temperature of 60 ºC and a force of 15 kN for 1 hour, figure 2.1. Embossing at 60 ºC, which is 
just below the melting point of PCL, ensures an optimal hot embossing and pattern transfer [4]. The system is then 
cooled to 20 ºC and the silicon wafer is removed, as shown in figure 2.2 and figure 3. The anti-sticking coating ensures 
that separation takes place between the coating and the polymer-drug film. The next process step is a deep reactive ion 
etch (DRIE) that separates the micro containers from the excess polymer-drug film, figure 2.3 and figure 4. The etching 
is performed with a DRIE using the following parameters for an anisotropic etch: O2 flow of 20 sccm, Ar flow 20 sccm, 
platen power 150 W, coil power 600, pressure of 4 mTorr, temperature of 10 ºC and time of 12 min. Finally, the 
individual containers are detached from the carrier wafer mechanically, figure 2.4. 
Drug release of the embossed polymer drug matrix is performed using a Pion μDISS profiler that utilizes UV 
spectroscopy to measure concentration over time. The drug release is performed using the biorelevant dissolution media 
Fasted State Simulated Intestinal Fluid (FaSSIF), to simulate the gastrointestinal fluids, and with a pH that is adjusted 
to pH 6.5 before the release. Experiments are conducted in beakers containing 10 ml FaSSIF media held at a temperature 
of 37 ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS & DISCUSSION 
The result of the fabrication process is SU-8 micro containers filled with a film consisting of polycaprolactone and 
furosemide, as shown in figure 5. The method is demonstrated to work on wafer scale level with 4 inch wafers. Our 
method for filling containers with a drug matrix can be applied to any polymeric drug that presents the following 
fabrication requirements. . The Tg of the polymer drug matrix must be lower than the one of the micro container material. 
The embossing temperature should be in-between the Tg polymer drug matrix material and the Tg of micro container 
material. This ensures a reflow of the polymer drug matrix without effect on the structural stability of the micro 
containers. Furthermore, the embossing temperature should not exceed Tm of the components to allow separation of the 
embossed stack following the cooling process. 
Drug release test is performed on the embossed drug matrix, as shown in figure 6 together with the release curve for 
crystalline furosemide powder and an amorphous spray dried furosemide powder. For the embossed polymer drug matrix 
more than 95% of the furosemide is released within the first 30 minutes. The release of the embossed polymer matrix 
shows improved drug release compared with crystalline furosemide. The release resembles the fast release seen from the 
amorphous furosemide. It is known that amorphous furosemide dissolves faster than crystalline [6], thus the furosemide 
in the embossed filmed exhibits amorphous characteristics. X-ray diffraction spectroscopy confirms the morphology and 
shows that the PCL furosemide films are amorphous before and after the embossing.    
 
 
 
1
2
3
4
Figure 3. Wafer with micro containers after 
polymer drug matrix embossing. 
Figure 4. SEM image showing polymer drug 
matrix embossed into micro containers and 
etched by DRIE. 
 
Figure 1. SEM image showing micro containers 
fabricated in SU-8 by a two step 
photolithography process 
Figure 2. Micro container filling process. 1-2 
Embossing polymer drug matrix into containers and 
removing the carrier wafer. 3 Etching of polymer 
drug matrix. 4 Mechanical release of containers 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
We have shown that it is possible to integrate filling of micro containers as part of the fabrication on a wafer scale 
level, thus enabling high volume production. The embossed PCL furosemide film shows fast drug release and the 
furosemide is found to be amorphous. Further development of micro containers for drug delivery includes the addition of 
a lid for controlled release and the exchange of SU-8 as container material with a biodegradable polymer 
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Figure 5. SEM image of released micro container 
filled with polymer drug matrix. The micro 
container is placed on carbon foil for ease of 
handling. 
Figure 6. Release curve of embossed furosemide 
polycaprolactone matrix showing cumulative release. 
As a reference the cumulative release for an 
amorphous furosemide powder and a crystalline is 
plotted. Release test is performed with pion μdiss 
profiler. Standard curve R2 value of 0.996. 
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a b s t r a c t
Biopolymer ﬁlms with a thickness of 100 lm are prepared using spin coating technique with solutions
consisting of 25 wt.% polycaprolactone or poly-L-lactide in dichloromethane. SU-8 stamps are fabricated
using three photolithography steps. The stamps are used to emboss 3Dmicrostructures in the biopolymer
ﬁlms. It is found that the best pattern transfer for the polycaprolactone ﬁlms is achieved just below the
melting point at 60 C. For the poly-L-lactide ﬁlms the best pattern transfer is achieved at 120 C.
 2010 Elsevier B.V. All rights reserved.
1. Introduction
Combining MEMS and NEMS with pharmaceutical research has
led to propositions of a number of new medical solutions [1].
Examples of these are the use of micro tablets for enhanced drug
delivery [2], and the fabrication of biodegradable polymer tubes
for tissue engineering [3]. The next step in developing newmedical
solutions is to replace classical micro fabrication materials such as
silicon and SU-8 with biodegradable polymers. In order to success-
fully do this, methods for fabricating 3D microstructures in
biodegradable polymers need to be developed.
In this work, we present 3Dmicrostructures fabricated in biode-
gradable polymer ﬁlms with a thickness of 105 lm. The polymer
microstructures are fabricated using hot embossing. The fabricated
structures have a shape like a well and could be used as drug
containers following the concept presented by Ainslie and co-
workers [2]. For the fabrication of the micro wells, thick ﬁlms of
biodegradable polymers in both polycaprolactone (PCL) and poly-
L-lactide (PLLA) are fabricated. Both PCL and PLLA are approved
by the food and drug administration (FDA) which makes them
obvious candidates for biomedical applications. PCL and PLLA are
new materials within the ﬁeld of micro fabrication and previous
work mainly revolves around mechanical property tests [4,5], deg-
radation studies [6–8] and tissue engineering [3,7,8]. Food science
is another area where biopolymers ﬁlms are of interest [9].
2. General method
The technique used to microstructure PLLA and PCL ﬁlms is hot
embossing with a stack as shown in Fig. 1. It consists of a biopoly-
mer ﬁlm on a silicon wafer and a SU-8 stamp on a silicon wafer.
The stamp is pressed into the preheated substrate. Subsequently,
substrate and stamp are cooled before separation.
3. Preparation of biopolymer ﬁlms
For biopolymer thick ﬁlm deposition by spin coating, PCL
granulate from Sigma–Aldrich (Mn/(kg/mol) = 70–90) and PLLA
granulate from Nature Works LLC, 2002D are used. The biopolymer
granulate is dissolved in dichloromethane (DCM) (25 wt.% poly-
mer) facilitated by heating to 50 C. The polymer solution is
manually dispensed onto a silicon wafer followed by acceleration
to the ﬁnal spin-speed which is maintained for 50 s. The PCL ﬁlms
are baked on a hotplate (90 C; 1 h) to remove the solvent resulting
in a ﬂat and even ﬁlm without bubbles. The PLLA ﬁlms are
degassed for 2 h before baking (220 C; 1 h) to avoid bubble
formation. 220 C is well above the melting point of PLLA which al-
low the polymer to reﬂow and to smoothen the surface.
The spin curves for both PCL and PLLA solutions are shown in
Fig. 2. Polymer ﬁlms are characterized by a proﬁlometer and ﬁlm
thicknesses of 40–110 lm are achieved. For the embossing exper-
iments polymer ﬁlms with a thickness of 100–110 lm are used.
4. Stamp fabrication
The stamp for the hot embossing is fabricated in SU-8. The
fabrication of the stamp is realized using a three step photolithog-
raphy process. First, a 2 lm thin SU-8 adhesion layer is spin coated
and ﬂood exposed with 250 mJ/cm2. The stamp structures are
then deﬁned with two subsequent thick SU-8 layers. A 40 lm
SU-8 layer is spincoated and softbaked for 2 h at 50 C. The SU-8
is exposed with 2  250 mJ/cm2 with a 30 s wait time and
post-exposure-baked for 6 h at 50 C. A second 65 lm thick SU-8
0167-9317/$ - see front matter  2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.mee.2010.12.014
⇑ Corresponding author.
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layer is spincoated and softbaked for 10 h at 50 C, before it is ex-
posed with 2  250 mJ/cm2 and post-exposure-baked at 50 C for
10 h. The SU-8 is developed in Propylene Glycol Methyl Ether Ace-
tate (PGMEA) for 20 min.
The stamp consists of 16 square arrays with 400 inverse well
structures as the one shown in Fig. 3. The outer ring is 110 ± 3 lm
high with an inner diameter of 300 lm. The inner disk is
66 ± 2 lm high with a diameter of 270 lm.
5. Embossing experiments
Preliminary experiments showed that adhesion between stamp
and PLLA is critical, as reuse of the stamp results in the SU-8 crack-
ing and minor pieces breaking off the stamp. Coating the stamp
with a hydrophobic FDTS anti-stiction layer [11] did not improve
the release of the SU-8 stamp. Deposition of a 140 nm ﬂuorocarbon
ﬁlm on top of the biopolymer by plasma polymerization using a
deep reactive ion etch device [12], results in a smooth separation
of stamp and biopolymer ﬁlm, thus enhancing the durability of
the stamps.
The embossing is performed with an EV Group 520 hot embos-
ser capable of exerting a force of 15 kN. A series of experiments is
conducted to optimize the pattern transfer from the SU-8 stamp
into the PLLA and PCL ﬁlms.
The hot embossing in PLLA is achieved by heating the substrate
and stamp well above the glass transition temperature (Tg  58 C
[10]). Force is then applied to press the stamp into the PLLA ﬁlm.
The sample is then cooled below Tg before the stamp is released
from the PLLA. For the PLLA experiments, force and time is kept
constant at 15 kN and 1 h respectively. The temperature is varied
80–140 C with 20 C intervals.
For the PCL, the hot embossing is carried out differently as Tg for
PCL is 60 C [10]. The sample is heated just below the melting
temperature at Tm = 65 C, embossed and cooled to room tempera-
ture before the stamp is released.
Force and time are kept constant at 15 kN and 3 h respectively.
Experiments are carried out at 25, 45, 55, 60, and 65 C.
For characterization of the embossed structures the wall height
is measured as this is the critical part of the well structure. The
height of the walls should correspond to the height of the inner
disk patterned in the second layer of SU-8 of the stamp, which is
approximately 65–68 lm.
6. Results and discussion
Successful embossing and easy stamp release are obtained for
the PLLA ﬁlm in the temperatures range 80–120 C. At 140 C,
the PLLA ﬁlm is very difﬁcult to separate from the stamp. As a con-
sequence, the stamp is partially destroyed with SU-8 structures
remaining in the PLLA ﬁlm. Fig. 4 shows a plot of the wall height
versus the distance from the center of the wafer of embossed PLLA
structures at 80, 100 and 120 C and the corresponding stamp
height. It is found that the thickness of the SU-8 layer is slightly
thinner at the center of the wafer and increases towards the edge.
Fig. 1. Schematic of the hot embossing process. (A) Stamp and substrate are heated,
(B) stamp pressed into substrate, (C) cooling followed by release, (D) cross sectional
view of SU-8 structure and (E) cross sectional view of biopolymer well structure.
Fig. 2. Spin curves for PLLA and PCL solutions in DCM solvent. The weight
percentage is 25% biopolymers to 75% DCM. The spin time is 50 s.
Fig. 3. Stamp structure shaped as an inverse well. The inner disk is 40 lm high and
the outer ring is 105 lm high.
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Embossing at 80 and 100 C yields a partial pattern transfer. It is
seen that the contour of the embossing at 120 C follows the con-
tour of the stamp height with a high accuracy. This indicates a very
good pattern transfer. The difference in height between the stamp
and the 120 C experiment could be caused by shrinkage in the
PLLA as it is cooled. Fig. 5 shows a SEM image of the well structure
embossed in PLLA.
Embossing in PCL has proven more difﬁcult than embossing in
the PLLA ﬁlms. For temperatures in the range from 25 to 45 C,
the pattern is not transferred and only minor indentation in the
PCL polymer ﬁlm is achieved. The experiments in the temperature
range 55–60 C show that it is possible to transfer the pattern from
stamp to substrate. The results show that it is very important to
control the temperature. At 55 C pattern heights between 7 and
35 lm are obtained whereas ﬁlm adhesion to the stamp occurs
at 65 C. This is probably due to the melting of the PCL ﬁlm and
strong adhesion to the stamp when it solidiﬁes. 60 C gives a good
pattern transfer with pattern heights increasing from 65 lm at the
center of the wafer to 68 lm at the edge of the wafer following the
contour of the SU-8 stamp.
A residual biopolymer layer remain after the embossing, this
layer can be removed with an oxygen plasma etch. The oxygen
plasma etch will also remove the ﬂuorocarbon layer used to en-
hance the durability of the stamps.
7. Conclusion
Biopolymer thick ﬁlms in PCL and PLLA have successfully been
deposited using spin coating. An SU-8 stamp has been fabricated
and used for hot embossing in PCL and PLLA ﬁlms. ‘‘The best pat-
tern transfer in PLLA is achieved by embossing with a force of
15 kN for 1 h at a temperature of 120 C’’.
The PCL embossing experiments show that the embossing tem-
perature is critical for a good pattern transfer and should be just
below the melting point.
It was shown that it is possible to fabricate 3D microstructures
in the FDA approved biopolymers, PCL and PLLA. The fabricated
well structures in PCL and PLLA are suitable carriers for drugs
and could be used as micro tablets.
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For Fresh Food Packaging and Food Serviceware
Ingeo biopolymer 2003D, a 
NatureWorks LLC product, is a 
thermoplastic resin derived from 
annually renewable resources and is 
specifically designed for use in fresh 
food packaging and food serviceware
applications. Ingeo biopolymer 2003D 
is a transparent general purpose 
extrusion grade that is used naturally 
or as part of a formulated blend.  This 
is a high molecular weight biopolymer 
grade that processes easily on 
conventional extrusion equipment.  
Extruded roll stock is readily 
thermoformable. See table at right for 
properties.
Applications
Potential applications for Ingeo
biopolymer 2003D include:
 Dairy containers
 Food serviceware
 Transparent food containers
 Hinged-ware
 Cold drink cups
Processing Information
Ingeo biopolymer 2003D is easily 
processed on conventional extrusion 
equipment. The material is stable in 
the molten state, provided that the 
drying procedures are followed. More 
detailed recommendations and 
processing requirements are found in 
the Ingeo biopolymer sheet extrusion 
processing guide, the purging technical 
data sheet, and the drying and 
crystallizing processing guide, all of 
which can be found at 
www.natureworksllc.com.
Machine Configuration
Ingeo biopolymer 2003D will process 
on conventional extrusion machinery 
with the following equipment: General 
purpose screw with L/D ratios from 
24:1 to 32:1 and compression ratio of 
2.5:1 to 3:1. Smooth barrels are 
recommended.
Process Details
Startup and Shutdown
Ingeo biopolymer 2003D is not 
compatible with a wide variety of 
commodity resins, and special purging 
sequences should be followed:
1. Clean extruder and bring 
temperatures to steady state with 
low viscosity, general purpose 
polystyrene or polypropylene.
2. Vacuum out hopper system to 
avoid contamination.
3. Introduce Ingeo biopolymers
into the extruder at the 
operating conditions used in 
Step 1.
4. Once Ingeo biopolymer has 
purged, reduce barrel 
temperatures to desired set 
points.
5. At shutdown, purge machine 
with high viscosity polystyrene or 
polypropylene.
Drying
In-line drying may be required. A
moisture content of less than 0.025% 
(250 ppm) is recommended to prevent 
viscosity degradation. Typical drying 
conditions for crystallized granules are 
2 hours at 195ºF (90ºC) or to a dew 
point of -40ºF (-40ºC), airflow rate of 
greater than 0.5 cfm/lbs per hour of 
resin throughput. The resin should not 
be exposed to atmospheric conditions 
after drying. Keep the package sealed 
until ready to use and promptly reseal 
any unused material. Pellets that have 
been exposed to the atmosphere for 
extended time periods will require 
additional drying time.  Amorphous 
regrind must be crystallized prior to 
drying, to assure efficient and effective 
drying.
Typical Material & Application Properties (1)
Physical Properties Ingeo 2003D ASTM Method
Specific Gravity 1.24 D792
MFR, g/10 min (210°C, 2.16kg) 6 D1238
Clarity Transparent
Mechanical Properties
Tensile Strength @ Break, psi (MPa) 7,700 (53) D882
Tensile Yield Strength, psi (MPa) 8,700 (60) D882
Tensile Modulus, kpsi (GPa) 500 (3.5) D882
Tensile Elongation, % 6.0 D882
Notched Izod Impact, ft-lb/in (J/m) 0.3 (16) D256
Shrinkage is similar to PET (2)
Heat Distortion Temperature (°C) 55 E2092
(1) Typical properties; not to be construed as specifications.
(2) Refer to Ingeo biopolymer Sheet Extrusion Processing Guide
Processing Temperature Profile (1)
Melt Temperature 410ºF 210ºC
Feed Throat 113ºF 45ºC
Feed Temperature 355ºF 180ºC
Compression
Section 375ºF 190ºC
Metering Section 390ºF 200ºC
Adapter 390ºF 200ºC
Die 375ºF 190ºC
Screw Speed 20-100 rpm
(1) These are starting points and may need to be 
optimized.
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Compostability
Composting is a method of waste 
disposal that allows organic materials 
to be recycled into a product that can 
be used as a valuable soil 
amendment. Ingeo biopolymer is made 
of polylactic acid, a repeating chain of 
lactic acid, which undergoes a 2-step 
degradation process. First, the 
moisture and heat in the compost pile 
attack the polymer chains and split 
them apart, creating smaller polymers, 
and finally, lactic acid. Microorganisms 
in compost and soil consume the 
smaller polymer fragments and lactic 
acid as nutrients. Since lactic acid is 
widely found in nature, a large number 
of organisms metabolize lactic acid. At 
a minimum, fungi and bacteria 
participate in this degradation process.
The end result of the process is carbon 
dioxide, water and also humus, a soil 
nutrient. This degradation process is 
temperature and humidity dependent. 
Regulatory guidelines and standards 
for composting revolve around four 
basic criteria: Material Characteristics, 
Biodegradation, Disintegration, and 
Ecotoxicity. Description of the 
requirements of these testing can be 
found in the appropriate geographical 
area: DIN V 54900-1 (Germany), EN 
13432 (EU), ASTM D 6400 (USA), 
GreenPla (Japan).  This grade of 
Ingeo biopolymer meets the
requirements of these four standards 
with limitation of maximum thickness 
3.2mm.
Food Packaging Status
U.S. Status
On January 3, 2002 FCN 000178 
submitted by NatureWorks LLC to FDA 
became effective.  This effective 
notification is part of list currently 
maintained on FDA’s website at 
http://www.cfsan.fda.gov/~dms/opa-
fcn.html
This grade of Ingeo biopolymer may 
therefore be used in food packaging 
materials and, as such, is a permitted 
component of such materials pursuant 
to section 201(s) of the Federal, Drug, 
and Cosmetic Act, and Parts 182, 184, 
and 186 of the Food Additive 
Regulations.  All additives and 
adjuncts contained in the referenced 
Ingeo biopolymer formulation meet the 
applicable sections of the Federal 
Food, Drug, and Cosmetic Act.  The 
finished polymer is approved for all 
food types and B-H use conditions.  
We urge all of our customers to 
perform GMP (Good Manufacturing 
Procedures) when constructing a 
package so that it is suitable for the 
end use.  Again, for any application, 
should you need further clarification, 
please do not hesitate to contact 
NatureWorks LLC.
European Status
This grade of Ingeo biopolymer 
complies with Commission Directive 
2002/72/EC as amended by 
2004/19/EC, 2005/79/EC, 2007/19/EC, 
2008/39/EC, and 2009/975/EC.  No 
SML’s for the above referenced grade 
exist in Commission Directive 
2002/72/EC or as amended by 
2004/19/EC, 2005/79/EC, 2007/19/EC, 
2008/39/EC, 2009/975/EC.
NatureWorks LLC would like to draw 
your attention to the fact that the EU-
Directive 2002/72/EC, which applies to 
all EU-Member States, includes a limit 
of 10 mg/dm2 of the overall migration 
from finished plastic articles into food.  
In accordance with EU-Directive 
2002/72/EC the migration should be 
measured on finished articles placed 
into contact with the foodstuff or 
appropriate food simulants for a period 
and at a temperature which are 
chosen by reference to the contact 
conditions in actual use, according to 
the rules laid down in EU-Directives 
93/8/EEC (amending 82/711/EEC) and 
85/572/EEC 
Please note that it is the responsibility 
of both the manufacturers of finished 
food contact articles as well as the 
industrial food packers to make sure 
that these articles in their actual use 
are in compliance with the imposed 
specific and overall migration 
requirements. 
This grade as supplied meets 
European Parliament and Council 
Directive 94/62/EC of 20 December 
1994 on packaging and packaging 
waste heavy metal content as 
described in Article 11.  It is 
recoverable in the form of material 
recycling, energy recovery, 
composting, and biodegradable per 
Annex II point 3, subject to the 
standards of the local community. 
Again, for any application, should you 
need further clarification, please do not 
hesitate to contact NatureWorks LLC.  
Bulk Storage
Recommendations
The resin silos recommended and 
used by NatureWorks LLC are 
designed to maintain dry air in the silo 
and to be isolated from the outside air. 
This design would be in contrast to an 
open, vented to atmosphere system 
that we understand to be a typical 
polystyrene resin silo.  Key features 
that are added to a typical (example: 
polystyrene) resin silo to achieve this 
objective include a cyclone and rotary 
valve loading system and some 
pressure vessel relief valves.  The dry 
air put to the system is sized to the 
resin flow rate out of the silo.  Not too 
much dry air would be needed and 
there may be excess instrument air 
(-30°F dew point) available in the plant 
to meet the needs for dry air.  Our 
estimate is 10 scfm for a 20,000 lb/hr 
rate resin usage.  Typically, resin 
manufacturers specify aluminum or 
stainless steel silos for their own use 
and avoid epoxy-lined steel
Ingeo™ Biopolymer 2003D
Page 3 of 3
NatureWorks, Ingeo and the Ingeo logo are trademarks or registered trademarks in the USA and other countries. NW2003D_033111V1
Safety and Handling Considerations
Material Safety Data (MSD) sheets for 
Ingeo biopolymers are available from 
NatureWorks LLC. MSD sheets are
provided to help customers satisfy their own 
handling, safety, and disposal needs, and 
those that may be required by locally 
applicable health and safety regulations, 
such as OSHA (U.S.A.), MAK (Germany), 
or WHMIS (Canada). MSD sheets are 
updated regularly; therefore, please request 
and review the most current MSD sheets 
before handling or using any product.
The following comments apply only to Ingeo
biopolymers; additives and processing aids 
used in fabrication and other materials used 
in finishing steps have their own safe-use 
profile and must be investigated separately.
Hazards and Handling Precautions
Ingeo biopolymers have a very low degree 
of toxicity and, under normal conditions of 
use, should pose no unusual problems from 
incidental ingestion, or eye and skin 
contact. However, caution is advised when 
handling, storing, using, or disposing of 
these resins, and good housekeeping and 
controlling of dusts are necessary for safe 
handling of product. Workers should be 
protected from the possibility of contact with 
molten resin during fabrication. Handling 
and fabrication of resins can result in the 
generation of vapors and dusts that may 
cause irritation to eyes and the upper 
respiratory tract. In dusty atmospheres, use 
an approved dust respirator. Pellets or 
beads may present a slipping hazard. Good 
general ventilation of the polymer 
processing area is recommended. At 
temperatures exceeding the polymer melt 
temperature (typically 170ºC), polymer can 
release fumes, which may contain 
fragments of the polymer, creating a 
potential to irritate eyes and mucous 
membranes. Good general ventilation 
should be sufficient for most conditions. 
Local exhaust ventilation is recom-mended 
for melt operations. Use safety glasses if 
there is a potential for exposure to particles 
which could cause mechanical injury to the 
eye. If vapor exposure causes eye 
discomfort, use a full-face respirator. No 
other precautions other than clean, body-
covering clothing should be needed for 
handling Ingeo biopolymers. Use gloves 
with insulation for thermal protection when 
exposure to the melt is localized.
Combustibility
Ingeo biopolymers will burn. Clear to white 
smoke is produced when product burns. 
Toxic fumes are released under conditions 
of incomplete combustion. Do not permit 
dust to accumulate. Dust layers can be 
ignited by spontaneous combustion or other 
ignition sources. When suspended in air, 
dust can pose an explosion hazard. 
Firefighters should wear positive-pressure, 
self-contained breathing apparatuses and 
full protective equipment. Water or water 
fog is the preferred extinguishing medium. 
Foam, alcohol-resistant foam, carbon 
dioxide or dry chemicals may also be used. 
Soak thoroughly with water to cool and 
prevent re-ignition.
Disposal
DO NOT DUMP INTO ANY SEWERS, ON 
THE GROUND, OR INTO ANY BODY OF 
WATER. For unused or uncontaminated 
material, the preferred options include 
recycling into the process or sending to an 
industrial composting facility, if available; 
otherwise, send to an incinerator or other 
thermal destruction device. For used or 
contaminated material, the disposal options 
remain the same, although additional 
evaluation is required. (For example, in the 
U.S.A., see 40 CFR, Part 261, 
“Identification and Listing of Hazardous 
Waste.”) All disposal methods must be in 
compliance with Federal, State/Provincial, 
and local laws and regulations.
Environmental Concerns
Generally speaking, lost pellets are not a 
problem in the environment except under 
unusual circumstances when they enter the 
marine environment. They are benign in 
terms of their physical environmental 
impact, but if ingested by waterfowl or 
aquatic life, they may mechanically cause
adverse effects. Spills should be minimized, 
and they should be cleaned up when they 
happen. Plastics should not be discarded 
into the ocean or any other body of water.
Product Stewardship
NatureWorks LLC has a fundamental duty 
to all those that make and use our products, 
and for the environment in which we live. 
This duty is the basis for our Product 
Stewardship philosophy, by which we 
assess the health and environmental 
information on our products and their 
intended use, then take appropriate steps 
to protect the environment and the health of 
our employees and the public.
Customer Notice
NatureWorks LLC encourages its 
customers and potential users of its 
products to review their applications for 
such products from the standpoint of 
human health and environmental quality. To 
help ensure our products are not used in 
ways for which they were not intended or 
tested, our personnel will assist customers 
in dealing with ecological and product 
safety considerations. Your sales 
representative can arrange the proper 
contacts. NatureWorks LLC literature, 
including Material Safety Data sheets, 
should be consulted prior to the use of the 
company’s products. These are available 
from your NatureWorks LLC representative.
NOTICE: No freedom from any patent owned by NatureWorks LLC or others is to be inferred. Because use conditions and applicable laws 
may differ from one location to another and may change with time, Customer is responsible for determining whether products and the 
information in this document are appropriate for Customer’s use and for ensuring that Customer’s workplace and disposal practices are in 
compliance with applicable laws and other governmental enactments. NatureWorks LLC assumes no obligation or liability for the information 
in this document. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A 
PARTICULAR USE ARE EXPRESSLY EXCLUDED.
NOTICE REGARDING PROHIBITED USE RESTRICTIONS:  NatureWorks LLC does not recommend any of its products, including samples, 
for use as: Components of, or packaging for, tobacco products; Components of products where the end product is intended for human or 
animal consumption; In any application that is intended for any internal contact with human body fluids or body tissues; As a critical 
component in any medical device that supports or sustains human life; In any product that is designed specifically for ingestion or internal use 
by pregnant women; and in any application designed specifically to promote or interfere with human reproduction.
For additional information please contact NatureWorks via our 
website on the tab called FAQ’s or by clicking here. 15305 Minnetonka Blvd., Minnetonka, MN 55345
Appendix E
PCL datasheet
111
Denmark Home 440744 - Polycaprolactone 
Description
Features and Benefits
Biodegradable polymer
Non-toxic, biodegradable in soil, broad miscibility, mechanical compatibility with many polymers and good adhesion to a broad spectrum of substrates. 
Packaging
250, 500 g in poly bottle 
5 g in glass bottle 
Application
Extrusion aid, die lubricant, mold release, pigment and filler dispersion aid and polyester segments in urethanes and block polyesters. 
Properties
Related Categories Biodegradable Polymers, Caprolactones, Materials 
Science, Polymer Science, PolymersMore...
form pellets (~3 mm) 
mol wt Mn 70,000-90,000 by GPC 
total impurities <1.0% water 
mp 60 °C(lit.) 
density 1.145 g/mL at 25 °C 
M
w
/M
n <2 
Documents
Bulk Quote-Order Product
MSDS
Specification Sheet
Certificate of Analysis
Certificate of Origin
Safety Information
Personal Protective Equipment  Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
WGK Germany  3 
Price and Availability
SKU-Pack Size Availability
Price
(EUR/DKK)
Quantity
440744-5G Estimated Delivery 19.12.2012 - FROM
31.10
223.91
0
440744-250G Estimated Delivery 19.12.2012 - FROM
108.50
781.20
0
440744-500G Estimated Delivery 19.12.2012 - FROM
200.50
1,443.59
0
440744 ALDRICH 
Polycaprolactone
M
n
70,000-90,000 by GPC
DOWNLOAD MSDS (PDF)
Synonym: 2-Oxepanone homopolymer, 6-Caprolactone polymer
CAS Number 24980-41-4 Linear Formula (C6H10O2)n
POPULAR DOCUMENTS:  SPECIFICATION SHEET (PDF)  |  FTIR (PDF)
Bulk orders?
ADD TO CART
Enter Lot No. Sen
Enter Lot No. Sen
Side 1 af 2Polycaprolactone Mn 70,000-90,000 by GPC | Sigma-Aldrich
19-12-2012http://www.sigmaaldrich.com/catalog/product/aldrich/440744?lang=en&region=DK
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2 CHAPTER 1. PROCESS DEVELOPMENT - SI STAMP
Step Process Parameters/Machine Illustration
1.1 PR for liftoﬀ Recipe: AZ4562-4inch-9.5um
SSE Spinner PR: AZ4562
Thickness: 10 μm
1.2 UV exposure Time: 2x50 s (30 s wait)
KS aligner Hard contact
1.3 Developer AZ351b -
Bond to a disk Time: 5 min.
1.4 Al deposition Wordentec
50 nm
1.5 PR removal/liftoﬀ
Acetone + ultrasound
1.6 PR for masking Recipe: AZ4562-4inch-9.5um
SSE Spinner PR: AZ4562
Thickness: 10 μm
1.7 UV exposure Time: 2x50 s (30 s wait) -
KS aligner Hard contact
32.1 ASE/pegasus etch Deep trench -
Etch depth: 60-200 μm
2.2 PR removal O2 ﬂow: 300 mL/min
Plasma Asher N2 ﬂow: 50 mL/min
Time: 30 min
Power 1000W
2.3 ASE/pegasus etch Deep trench -
Etch depth: 60 μm
2.4 Al removal
H2O:H3PO4 1:2 50 ◦C
Etch rate 100nm/min 1 min etch time
2.5 Oxidation Bohr-drive-in
wet1100 50 min
temp: 1100◦C Thickness 600nm
2.6 Oxide removal HF-dip
BHF etch rate : 75 nm/min 10 mins
2.5 MVD coating
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Process for fabrication of Ni stamp
Johan Nagstrup
Group: Nanoprobes
Batch# 3d biopolymer
Revision nr: Rev #1
Wafer choise: Cheapest available
Esben Krirk Mikkelsen s082641
Saro Ulver Hierwagen s080297
Figure 1: Alignment marks
1
Step Process Parameter Graphic Note
1 Wet oxide Bohr drive in
wet oxide 1100 ◦C
500nm - 50 min
6 wafers
1.1 Oxide mea-
surement
Filmtek Pro-
ﬁleometer
5 points measure-
ment
1 wafers
2 Spin coating
AZ resist
1.5μm
Track 1
HMDS
6 wafers
3 Positive photo
lithography
Hard contact 3-5
sec
Mask: Container bottom
6 wafers
4 Develop 60sec 6 wafers
5 BHF 10min
etch rate 75
nm/min. zero
tolerance.
6 wafers
5.1 Dektak Oxide thickness 1 wafers
6 Resist remove Acetone
Rough 1min
Fine 1min
6 wafers
7 Spin coating
AZ resist
1.5 μm
Track 1
HMDS
2
Step Process Parameter Graphic Note
8 Positive
photo lithog-
raphy
5-7 sec Mask: Container walls
9 Develop 60 sec 2 wafers
10 Etch Pegasus/Ase
20 μm ± 2μm
Mask: 1.5 μm resist
10.1 Dektak Etch depth 1 wafers
11 Remove Re-
sist plasma
asher
Acetone Mask: 100 nm Al
12 Etch Pegasus
80 μm ± 2μm
12.1 Dektak Etch depth 1 wafers
13 Wet etch Ox-
ide
Repeat step 8-12 with the rest of
the wafers
14 SEM 1 wafer
3
Step Process Parameter Graphic Note
15 Optinoal ox-
ide following
SEM inspec-
tion
RCA cleaning
WET oxide 1100
60 min
16 Deposit
Ti/Cr
Lesker 1 wafer
Good coverage needed
17 Deposit Au Lesker Good coverage needed
18 Electro plat-
ing Ni
Process optimization with
Mikkel Mar (step 18-20)
19 Rub down
top of Ni
20 Remove Si
with KOH
4
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Appendix J
Stencil mask, CO2-laser
parameters
Process parameters used in the fabrication of transparent foil stencil masks:
Figure J.1: For the design of the stencil, the spot tool is used along with the parameters
shown to the left of the spots.
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